

## Section 1: 10-Q (10-Q)

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549  
**FORM 10-Q**

(Mark One)

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the quarterly period ended **March 31, 2019**  
or
- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission file number: **001-32209**

### **WELLCARE HEALTH PLANS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**47-0937650**  
(I.R.S. Employer  
Identification No.)

**8735 Henderson Road, Renaissance One**  
**Tampa, Florida**  
(Address of Principal Executive Offices)

**33634**  
(Zip Code)

**(813) 290-6200**  
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer  Accelerated filer  Non-accelerated filer   
Smaller reporting company  Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of April 29, 2019, there were 50,303,407 shares of the registrant's common stock, par value \$0.01 per share, outstanding.

WELLCARE HEALTH PLANS, INC.

TABLE OF CONTENTS

	<b>Page</b>
<b>Part I — FINANCIAL INFORMATION</b>	
Item 1. Financial Statements	
Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2019 and 2018 (unaudited)	<a href="#"><u>2</u></a>
Condensed Consolidated Balance Sheets as of March 31, 2019 and December 31, 2018 (unaudited)	<a href="#"><u>3</u></a>
Condensed Consolidated Statements of Changes in Stockholders' Equity for the three months ended March 31, 2019 and 2018 (unaudited)	<a href="#"><u>4</u></a>
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2019 and 2018 (unaudited)	<a href="#"><u>5</u></a>
Notes to Condensed Consolidated Financial Statements (unaudited)	<a href="#"><u>6</u></a>
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	<a href="#"><u>29</u></a>
Item 3. Quantitative and Qualitative Disclosures About Market Risk	<a href="#"><u>46</u></a>
Item 4. Controls and Procedures	<a href="#"><u>46</u></a>
<b>Part II — OTHER INFORMATION</b>	
Item 1. Legal Proceedings	<a href="#"><u>47</u></a>
Item 1A. Risk Factors	<a href="#"><u>47</u></a>
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	<a href="#"><u>49</u></a>
Item 3. Defaults Upon Senior Securities	<a href="#"><u>50</u></a>
Item 4. Mine Safety Disclosures	<a href="#"><u>50</u></a>
Item 5. Other Information	<a href="#"><u>50</u></a>
Item 6. Exhibits	<a href="#"><u>50</u></a>
Signatures	<a href="#"><u>52</u></a>
Exhibit Index	<a href="#"><u>51</u></a>

Part I — FINANCIAL INFORMATION

Item 1. Financial Statements.

WELLCARE HEALTH PLANS, INC.  
 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME  
 (Unaudited) (In millions, except per share and share data)

	For the Three Months Ended March 31,	
	2019	2018
<b>Revenues:</b>		
Premium	\$ 6,609.4	\$ 4,626.3
Products and services	115.8	—
Investment and other income	37.0	19.9
Total revenues	6,762.2	4,646.2
<b>Expenses:</b>		
Medical benefits	5,831.7	3,962.0
Costs of products and services	111.8	—
Selling, general and administrative	503.8	355.9
ACA industry fee	—	81.5
Medicaid premium taxes	31.7	32.1
Depreciation and amortization	69.6	36.4
Interest	29.5	17.1
Total expenses	6,578.1	4,485.0
Income before income taxes and equity in losses of unconsolidated subsidiaries	184.1	161.2
Equity in earnings (losses) of unconsolidated subsidiaries	0.8	(2.7)
Income before income taxes	184.9	158.5
Income tax expense	33.5	56.8
Net income	\$ 151.4	\$ 101.7
<b>Other comprehensive income (loss):</b>		
Change in net unrealized gains and losses on available-for-sale securities, before tax	18.5	(10.3)
Income tax expense (benefit) related to other comprehensive income	4.7	(2.4)
Other comprehensive income (loss), net of tax	13.8	(7.9)
Comprehensive income	\$ 165.2	\$ 93.8
<b>Earnings per common share:</b>		
Basic	\$ 3.02	\$ 2.28
Diluted	\$ 2.98	\$ 2.25
<b>Weighted average common shares outstanding:</b>		
Basic	50,100,509	44,605,892
Diluted	50,842,304	45,196,127

See notes to unaudited condensed consolidated financial statements.

**WELLCARE HEALTH PLANS, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**  
(Unaudited) (In millions, except share data)

	<u>March 31, 2019</u>	<u>December 31, 2018</u>
<b>Assets</b>		
Current Assets:		
Cash and cash equivalents	\$ 3,235.3	\$ 3,653.9
Short-term investments	968.6	830.1
Premiums receivable, net	1,567.6	1,223.4
Pharmacy rebates receivable, net	550.0	460.6
Funds receivable for the benefit of members	331.6	187.3
Prepaid expenses and other current assets, net	1,127.6	477.1
<b>Total current assets</b>	<b>7,780.7</b>	<b>6,832.4</b>
Property, equipment and capitalized software, net	424.9	428.2
Goodwill	2,206.4	2,227.7
Other intangible assets, net	986.0	996.2
Long-term investments	1,057.6	813.2
Restricted cash, cash equivalents and investments	274.3	234.7
Other assets	268.8	18.7
Assets of discontinued operations	207.2	213.6
<b>Total Assets</b>	<b>\$ 13,205.9</b>	<b>\$ 11,764.7</b>
<b>Liabilities and Stockholders' Equity</b>		
Current Liabilities:		
Medical benefits payable	\$ 3,212.6	\$ 2,897.4
Unearned premiums	16.9	1.4
Accounts payable and accrued expenses	1,304.9	964.6
Funds payable for the benefit of members	1,051.8	693.3
Other payables to government partners	491.1	458.9
<b>Total current liabilities</b>	<b>6,077.3</b>	<b>5,015.6</b>
Deferred income tax liability, net	149.0	134.2
Long-term debt, net	2,127.3	2,126.4
Other liabilities	253.9	34.9
Liabilities of discontinued operations	207.2	213.6
<b>Total Liabilities</b>	<b>8,814.7</b>	<b>7,524.7</b>
Commitments and contingencies (see Note 14)		
Stockholders' Equity:		
Preferred stock, \$0.01 par value (20,000,000 authorized, no shares issued or outstanding)	—	—
Common stock, \$0.01 par value (100,000,000 authorized, 50,302,215 and 49,993,219 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively)	0.5	0.5
Paid-in capital	1,967.1	1,981.1
Retained earnings	2,418.7	2,267.3
Accumulated other comprehensive income (loss)	4.9	(8.9)
<b>Total Stockholders' Equity</b>	<b>4,391.2</b>	<b>4,240.0</b>
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 13,205.9</b>	<b>\$ 11,764.7</b>
<i>See notes to unaudited condensed consolidated financial statements.</i>		

**WELLCARE HEALTH PLANS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**  
(Unaudited) (In millions, except share data)

	Common Stock			Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Total Stockholders' Equity
	Shares	Amount	Paid in Capital			
<b>Balance at January 1, 2019</b>	49,993,219	\$ 0.5	\$ 1,981.1	\$ 2,267.3	\$ (8.9)	\$ 4,240.0
Common stock issued for vested equity-compensation awards	451,484	—	—	—	—	—
Repurchase and retirement of shares to satisfy tax withholding requirements	(142,488)	—	(36.8)	—	—	(36.8)
Stock-based compensation expense, net of forfeitures	—	—	22.8	—	—	22.8
Comprehensive income	—	—	—	151.4	13.8	165.2
<b>Balance at March 31, 2019</b>	<u>50,302,215</u>	<u>\$ 0.5</u>	<u>\$ 1,967.1</u>	<u>\$ 2,418.7</u>	<u>\$ 4.9</u>	<u>\$ 4,391.2</u>
<b>Balance at January 1, 2018</b>	44,522,988	\$ 0.4	\$ 591.5	\$ 1,827.5	\$ (2.7)	\$ 2,416.7
Common stock issued for vested stock-based compensation awards	334,521	—	—	—	—	—
Repurchase and retirement of shares to satisfy tax withholding requirements	(104,274)	—	(20.2)	—	—	(20.2)
Stock-based compensation expense, net of forfeitures	—	—	12.1	—	—	12.1
Comprehensive income (loss)	—	—	—	101.7	(7.9)	93.8
<b>Balance at March 31, 2018</b>	<u>44,753,235</u>	<u>\$ 0.4</u>	<u>\$ 583.4</u>	<u>\$ 1,929.2</u>	<u>\$ (10.6)</u>	<u>\$ 2,502.4</u>

*See notes to unaudited condensed consolidated financial statements.*

**WELLCARE HEALTH PLANS, INC.**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited, in millions)

	For the Three Months Ended March 31,	
	2019	2018
<b>Cash flows from operating activities:</b>		
Net income	\$ 151.4	\$ 101.7
<b>Adjustments to reconcile net income to cash flows from operating activities:</b>		
Depreciation and amortization	69.6	36.4
Stock-based compensation expense	22.8	12.1
Deferred taxes, net	6.6	(19.5)
Other, net	10.1	5.1
<b>Changes in operating accounts, net of effects from acquisitions and divestitures:</b>		
Premiums receivable, net	(348.5)	(187.9)
Pharmacy rebates receivable, net	(89.4)	(45.6)
Medical benefits payable	315.2	64.0
Unearned premiums	15.5	527.0
Other receivables/payables to government partners	32.2	(15.8)
Prepaid and other current assets	(110.9)	(7.4)
Accrued liabilities and other, net	(104.6)	(24.4)
Net cash (used in) provided by operating activities	(30.0)	445.7
<b>Cash flows from investing activities:</b>		
Purchases of investments	(979.0)	(387.9)
Proceeds from sales and maturities of investments	529.6	171.5
Additions to property, equipment and capitalized software, net	(38.1)	(24.2)
Net cash used in provided by investing activities	(487.5)	(240.6)
<b>Cash flows from financing activities:</b>		
Repurchase and retirement of shares to satisfy employee tax withholding requirements	(36.8)	(20.2)
Funds received for the benefit of members, net	170.7	416.2
Other, net	1.3	21.4
Net cash provided by financing activities	135.2	417.4
(Decrease) increase in cash, cash equivalents and restricted cash and cash equivalents	(382.3)	622.5
Balance at beginning of period	3,716.6	4,263.0
Balance at end of period	\$ 3,334.3	\$ 4,885.5
<b>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</b>		
Cash paid for taxes, net of refunds	\$ 6.7	\$ 2.0
Cash paid for interest	\$ 54.6	\$ 32.1
<b>SUPPLEMENTAL DISCLOSURES OF NON-CASH TRANSACTIONS:</b>		
Non-cash additions to property, equipment, and capitalized software	\$ 5.8	\$ 3.0

See notes to unaudited condensed consolidated financial statements.

**WELLCARE HEALTH PLANS, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited) (In millions, except member, per share and share data)**

**1. ORGANIZATION, BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES**

WellCare Health Plans, Inc. (the "Company," "we," "us," or "our") focuses primarily on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs primarily through Medicaid, Medicare Advantage ("MA") and Medicare Prescription Drug Plans ("PDP"), as well as individuals in the Health Insurance Marketplace. As of March 31, 2019, we served approximately 6.3 million members nationwide.

As of March 31, 2019, we operated Medicaid health plans, including states where we receive Medicaid premium revenues associated with dually eligible special needs plans, in Arizona, Florida, Georgia, Hawaii, Illinois, Kentucky, Michigan, Missouri, Nebraska, New Jersey, New York, South Carolina and Texas.

In addition, as of March 31, 2019, we also operated MA coordinated care plans ("CCPs") in Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maine, Michigan, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina, Tennessee and Texas. We also offered stand-alone Medicare PDPs nationwide.

In September 2018, we completed the acquisition of Meridian Health Plan of Michigan, Inc., Meridian Health Plan of Illinois, Inc., and MeridianRx, LLC, a pharmacy benefit manager ("PBM") (collectively, "Meridian"). As a result of the acquisition, we expanded our Medicaid portfolio through the addition of Michigan; expanded our Medicaid presence in Illinois; and acquired an integrated PBM platform. Meridian also serves MA members in Illinois, Indiana, Michigan, and Ohio, as well as Health Insurance Marketplace members in Michigan.

**Basis of Presentation**

The accompanying unaudited condensed consolidated balance sheets and statements of comprehensive income, changes in stockholders' equity, and cash flows include our accounts and the accounts of our subsidiaries over which we have control or are the primary beneficiary. We eliminated all intercompany accounts and transactions.

The accompanying unaudited condensed consolidated interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP"). Accordingly, certain financial information and footnote disclosures normally included in financial statements prepared in accordance with GAAP, but that are not required for interim reporting purposes, have been condensed or omitted. The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements and notes thereto, for the fiscal year ended December 31, 2018, included in our Annual Report on Form 10-K ("2018 Form 10-K"), which was filed with the U.S. Securities and Exchange Commission ("SEC") in February 2019. Results for the interim periods presented are not necessarily indicative of results that may be expected for the entire year or any other interim period.

In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all normal recurring adjustments that we consider necessary for the fair presentation of our financial position, results of operations and cash flows for the interim periods presented. In accordance with GAAP, we make certain estimates and assumptions that affect the amounts reported in the condensed consolidated interim financial statements and accompanying notes. We base these estimates, including assumptions as to the annualized tax rate, on our knowledge of current events and anticipated future events and evaluate and update our assumptions and estimates on an ongoing basis; however, actual results may differ from our estimates. We evaluated all material events subsequent to the date of these condensed consolidated interim financial statements. Certain reclassifications were made to 2018 financial information to conform to the 2019 presentation.

### *Pharmacy Benefit Manager*

The external revenues and costs for our PBM business are reported within "Products and Services" and "Cost of Products and Services", respectively, on the condensed consolidated statements of comprehensive income. Products and services revenues from our PBM consist of the prescription price (ingredient cost plus dispensing fee) negotiated with the retail pharmacies with which we have contracted, plus any associated administrative fees. This revenue is recognized when the claim is processed. We have the contractual obligation to pay network pharmacies for benefits provided to participating members and, therefore, act as principal in the arrangement and reflect the total prescription price as revenue, on a gross basis, in accordance with applicable accounting guidance. Costs of products and services is recognized at the time prescriptions are dispensed by pharmacies in the PBM's network to eligible members and consists primarily of ingredient costs and dispensing fees paid to retail pharmacies with which we have contracted. The overall results of our PBM business are immaterial.

### *Aetna Part D Membership Reinsurance*

In November 2018, we completed the purchase of Aetna Inc.'s ("Aetna") entire standalone Medicare Part D prescription drug plan membership ("Aetna Part D membership"). In connection with the purchase, we also entered into an administrative services agreement and a reinsurance agreement pursuant to which Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership, effective for plan year 2019. We remain primarily liable to policyholders under this ceded insurance contract and are contingently liable for amounts recoverable from Aetna in the event that they do not meet their contractual obligations. In the normal course, we evaluate the financial condition of our reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. As of March 31, 2019, related to the Aetna Part D membership, our condensed consolidated balance sheet included reinsured receivables of \$30.8 million, primarily related to premiums receivable, and reinsured payables of \$482.8 million, primarily related to pharmacy claims payables. These reinsured receivables and payables were included in prepaid expenses and other current assets, net, and accounts payable and accrued liabilities, respectively. The resulting net reinsurance recoverables of \$452.0 million was included in prepaid expenses and other current assets, net on the condensed consolidated balance sheet. There were no reinsurance recoverables or reinsurance liabilities relating to the Aetna Part D membership recorded as of December 31, 2018.

In our condensed consolidated statements of comprehensive income, premium revenue and medical benefits were reported net of amounts ceded under this Aetna reinsurance arrangement. Premium revenue and medical benefits expense ceded relating to the Aetna Part D membership were \$501.0 million and \$473.7 million, respectively, for the three months ended March 31, 2019.

### *Unconsolidated Subsidiaries*

We work with physicians and other health care professionals to operate Accountable Care Organizations ("ACOs") under the Medicare Shared Saving Program ("MSSP") and Next Generation ACO Models. ACOs were established by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively the "ACA") to reward integrated, efficient care and allow providers to share in any savings they achieve as a result of improved quality and operational efficiency.

These ACOs are generally formed as limited liability companies. The ACOs are considered variable interest entities ("VIEs") under GAAP as these entities do not have sufficient equity to finance their own operations without additional financial support. We own a majority interest in our ACOs; however, we share the power to direct the activities that most significantly affect the ACOs with health care providers that are minority owners in the ACOs. This power is shared pursuant to the structure of the management committee of each of the ACOs. Accordingly, we have determined that we are not the primary beneficiary of the ACOs; therefore, we cannot consolidate their results. We perform an ongoing qualitative assessment of our variable interests in VIEs to determine whether we have a controlling financial interest and would therefore be considered the primary beneficiary of the VIE.

We account for our participation in the ACOs using the equity method. Gains and losses are immaterial and are reported on the face of our condensed consolidated statements of comprehensive income as equity in earnings (losses) of unconsolidated subsidiaries.



## Significant Accounting Policies

Below is a discussion of our significant accounting policies, which affected the comparability of our consolidated results of operations, financial condition or cash flows for the periods presented. Refer to Note 2 - *Summary of Significant Accounting Policies* to the consolidated financial statements included in our 2018 Form 10-K for a complete discussion of all of our significant accounting policies.

### Premium Receivables and Unearned Premiums

We record premiums earned but not received as premiums receivable and record premiums received in advance of the period of service as unearned premiums in our condensed consolidated balance sheets. A complete discussion of premiums receivable and unearned premiums is included in Note 2 - *Summary of Significant Accounting Policies* to the consolidated financial statements included in our 2018 Form 10-K. The premium receivable balance at March 31, 2019 is primarily related to Medicaid contracts with our state partners of approximately \$1.2 billion, as well as net risk-adjusted premiums receivable under our MA and PDP contracts of approximately \$364.0 million.

#### *Medicaid Risk-Adjusted Premiums and Retroactive Rate Changes*

As discussed further in Note 2 - *Summary of Significant Accounting Policies* to the consolidated financial statements included in our 2018 Form 10-K, Medicaid premium rate changes are recognized in the period the change becomes effective, when the effect of the change in the rate is reasonably estimable and collection is assured. In some instances, our Medicaid premiums are subject to risk score adjustments based on the health profile of our membership. Generally, the risk score is determined by the state agency's analysis of encounter submissions of processed claims data to determine the acuity of our membership relative to the entire state's Medicaid membership. The frequency of when states adjust premiums varies, but is usually done quarterly or semi-annually on a retrospective basis. We recognize periodic changes to risk-adjusted premiums as revenue when the amounts are determinable and collection is reasonably assured. Premiums receivable in our condensed consolidated balance sheets include net risk-adjusted premiums receivable from our Medicaid state partners related to retroactive rate changes and risk score adjustments of \$121.5 million and \$54.4 million as of March 31, 2019 and December 31, 2018, respectively.

### Medicare Part D Settlements

We receive certain Part D prospective subsidy payments from the Centers for Medicare & Medicaid Services ("CMS") for our MA and PDP members as a fixed monthly per member amount, based on the estimated costs of providing prescription drug benefits over the plan year, as reflected in our bids. A discussion of the subsidy components under Part D is included in Note 2 - *Summary of Significant Accounting Policies* to the consolidated financial statements included in our 2018 Form 10-K. CMS will fully reimburse these subsidies, or recoup overpaid subsidies made during the plan year, as part of its annual settlement process that typically occurs in the fourth quarter of the subsequent year and, accordingly, there is no insurance risk to us. Therefore, amounts received for these subsidies are not considered premium revenue, and are reported, net of the subsidy benefits paid, as funds receivable (payable) for the benefit of members in the condensed consolidated balance sheets. As of March 31, 2019 and December 31, 2018, our condensed consolidated balance sheets primarily include CMS Part D payables for the 2018 and 2016 plan years. Our condensed consolidated balance sheet as of March 31, 2019 additionally includes a payable for the 2019 plan year. We expect to settle a majority of the 2016 and 2018 net payables during the remainder of 2019.

### ACA Industry Fee

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 imposed certain new taxes and fees, including an annual premium-based health insurance industry assessment (the "ACA industry fee") on health insurers, which began in 2014. In January 2018, Congress approved a one-year moratorium of the ACA industry fee for 2019, which also eliminated the Medicaid ACA industry fee reimbursement from our state government partners for 2019. Accordingly, we did not incur ACA industry fee expense nor recognize any Medicaid ACA industry fee reimbursement revenue for the three months ended March 31, 2019. We incurred \$81.5 million for the ACA industry fee for the three months ended March 31, 2018. Additionally, we recognized \$64.7 million of Medicaid ACA industry fee reimbursement revenue as premium revenue for the three months ended March 31, 2018.

### Recently Adopted Accounting Standards

In June 2018, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2018-07, "*Compensation-Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting*." This update expands the scope of Topic 718, which currently only includes share-based payments issued to

employees, to include share-based payments issued to non-employees for goods and services. This guidance was effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In February 2018, the FASB issued ASU 2018-02 "*Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income*", which allows entities to reclassify stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 from accumulated other comprehensive income to retained earnings. The guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance prospectively on January 1, 2019. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In March 2017, the FASB issued ASU No. 2017-08, "*Receivables—Nonrefundable Fees and Other Costs (Subtopic 310-20): Premium Amortization on Purchased Callable Debt Securities*". This update shortens the amortization period for the premium on certain purchased callable debt securities to the earliest call date. Previously, entities generally amortize the premium as a yield adjustment over the contractual life of the security. The new guidance does not change the accounting for purchased callable debt securities held at a discount. This guidance is effective for interim and annual periods beginning after December 15, 2018. We adopted this guidance on January 1, 2019 on a modified retrospective basis. The adoption of this guidance did not have a material effect on our consolidated results of operations, financial condition or cash flows.

In February 2016, the FASB issued ASU 2016-02, "*Leases (Topic 842)*", which for operating leases, requires a lessee to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments in its balance sheet. This standard also requires a lessee to recognize a single lease cost, calculated so that the cost of the lease is allocated over the lease term, on a generally straight-line basis. Subsequently, in July 2018, the FASB issued ASU 2018-11, "*Leases (Topic 842), Targeted Improvements*" which, among other things, allows companies to elect an optional transition method to apply the new lease standard through a cumulative-effect adjustment, if any, in the period of adoption, rather than in the earliest period presented. We adopted the standard on January 1, 2019 using the optional transition method. We elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classifications for existing leases. Additionally, we elected the practical expedient to not separate non-lease components from the associated lease component. As part of the adoption process, we implemented a new lease accounting system. The adoption of this guidance resulted in the initial recognition of operating lease right-of-use assets of approximately \$259.5 million, operating lease liabilities of approximately \$277.3 million and the elimination of \$17.8 million of straight-line lease liabilities, as of January 1, 2019. This guidance did not have a material effect on our consolidated results of operations or cash flows.

### **Accounting Standards Pending Adoption**

In August 2018, the FASB issued ASU 2018-15, "*Intangibles-Goodwill and Other-Internal-Use Software: Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract*", which requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.

In June 2016, the FASB issued ASU 2016-13, "*Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments*," which requires entities to use a current expected credit loss model, which is a new impairment model based on expected losses rather than incurred losses. Under this model, an entity would recognize an impairment allowance equal to its current estimate of all contractual cash flows that the entity does not expect to collect from financial assets measured at amortized cost. The entity's estimate would consider relevant information about past events, current conditions, and reasonable and supportable forecasts, which will result in recognition of lifetime expected credit losses upon loan origination. ASU 2016-13 is effective for interim and annual reporting periods beginning after December 15, 2019, with early adoption permitted for annual reporting periods beginning after December 15, 2018. We are currently assessing the effect this guidance will have on our consolidated results of operations, financial condition or cash flows.

## **2. CENTENE PLAN OF MERGER AND ACQUISITIONS**

### **Centene Plan of Merger**

On March 26, 2019, we entered into an Agreement and Plan of Merger (the "Merger Agreement") with Centene Corporation ("Centene") under which Centene will acquire us for a combination of cash and stock. Under the terms of the Merger Agreement, our shareholders will receive \$120.00 in cash and 3.38 shares of Centene common stock for each share of our common stock. The proposed transaction is subject to customary closing conditions, including, but not limited to, the approval of the Merger Agreement by our stockholders, the approval of the share issuance of Centene stock by Centene's stockholders, and the receipt of U. S. federal antitrust clearance and certain other required regulatory approvals. The transaction is expected to close in the first half of 2020.

The Merger Agreement includes restrictions on the conduct of our business prior to completion of the Centene Transaction or termination of the Merger Agreement, generally requiring us to conduct our business in the ordinary course. However, we are subject to various specified restrictions unless we obtain Centene's prior written consent, which may not be unreasonably withheld, delayed or conditioned, or expressly contemplated or permitted by the Merger Agreement or as required by applicable law. Among other things and in each case subject to certain exceptions, we may not:

- incur additional indebtedness (excluding borrowings under our Revolving Credit Facility (as defined below) that are used to manage our ordinary course cash flow needs);
- issue additional shares of our common stock, repurchase our common stock, or pay dividends;
- acquire assets, securities or property, dispose of businesses or assets; or
- authorize any payment of, accrual or commitment for capital expenditures in any calendar year that would exceed by more than 110% the aggregate amount of capital expenditures budgeted for such year.

### **Aetna Medicare Part D Asset Acquisition**

As discussed in Note 1 - *Organization, Basis of Presentation and Significant Accounting Policies* of this 2019 Form 10-Q, in November 2018, we completed the purchase of Aetna's Part D membership for total cash consideration of \$107.2 million, which is subject to certain true-up provisions. These membership assets are recorded within other intangible assets, net in the condensed consolidated balance sheets as of March 31, 2019 and December 31, 2018, and have a weighted-average useful life of eight years beginning in 2020. Per the terms of the agreement, Aetna provides administrative services to, and retains financial risk of, the Aetna Part D membership through 2019. Therefore, the Aetna Part D membership is excluded from our membership and has had, or is expected to have, an immaterial effect on our results of operations until January 1, 2020.

### **Meridian Business Acquisition**

On September 1, 2018 (the "Effective Date"), we acquired Meridian for an estimated purchase price of approximately \$2.5 billion in cash, subject to certain purchase price adjustments, as described in the purchase agreement. The Meridian acquisition was funded through a combination of cash on hand, our Revolving Credit Facility, net proceeds from the August 2018 issuance of our 5.375% of Senior Notes due 2026 ("2026 Notes") and net proceeds from an issuance of shares of our common stock. We included the results of Meridian's operations since the Effective Date in our condensed consolidated financial statements.

The following table summarizes the estimated fair values of major classes of assets acquired and liabilities assumed at the Effective Date, based on our valuation assumptions, reconciled to the total consideration transferred.

<b>Assets</b>		(in millions)
Cash, cash equivalents and restricted cash	\$	484.4
Investments, including restricted investments		180.4
Premiums receivable, net		379.6
Other current assets		146.2
Property, equipment and capitalized software, net		49.3
Goodwill		1,539.4
Other intangible assets, net		622.0
Fair value of total assets acquired	\$	3,401.3
<b>Liabilities</b>		
Medical benefits payable	\$	534.3
ACA Fee liability		66.5
Other liabilities		280.4
Fair value of liabilities assumed		881.2
Fair value of net assets acquired	\$	2,520.1

The fair value results from judgments about future events, which reflect certain uncertainties and rely on estimates and assumptions. The judgments used to determine the fair value assigned to each class of assets acquired and liabilities assumed, as well as intangible asset lives, can materially affect our operating results. As of the Effective Date, the expected fair value of all current assets and liabilities approximated their historical cost. As of March 31, 2019, we have preliminarily determined the fair value of assets acquired and liabilities assumed; however, the final fair values may be subject to, (i) the final valuation of intangible assets related to memberships and trade names, (ii) the final assessment and valuation of certain other assets acquired and liabilities assumed, including premiums receivable, property, equipment and capitalized software, medical benefits payable and other liabilities and (iii) the final assessment and valuation of certain income tax amounts. Therefore, the final fair values of the assets acquired and liabilities assumed may vary significantly from our preliminary estimates.

#### *Identifiable intangible assets acquired*

Under the Hart-Scott-Rodino Antitrust Improvements Act and other relevant laws and regulations, there were significant limitations on our ability to obtain specific information about Meridian's intangible assets prior to completion of the acquisition in September 2018. As of March 31, 2019, certain of the more significant assumptions inherent in the development of intangible asset fair values, including the following, are preliminary.

- final membership attrition rates;
- final discount rates selected to measure the risks inherent in the future cash flows;
- key assumptions in the valuation of the acquired technology, including, but not limited to, estimated costs associated with developers' salaries, external direct costs of materials and services; and the estimated time to replace the acquired software applications; and
- working capital adjustments and the assessment of the assets' life cycle, among other key assumptions.

The following table summarizes the preliminary fair values and weighted average useful lives for identifiable intangible assets acquired in the Meridian acquisition as of the Effective Date of the acquisition. These preliminary estimates of fair value and weighted-average useful life may be different from the final acquisition accounting, and the difference could have a material effect on the consolidated financial statements.

	Gross Fair Value (in millions)	Weighted Average Useful Life (in years)
Membership	\$ 406.6	8.1
Tradenames	110.4	4.9
Provider network	8.3	15.0
Technology and other	96.7	5.8
<b>Total</b>	<b>\$ 622.0</b>	<b>7.3</b>

### Goodwill

We recorded \$1.5 billion for the valuation of goodwill for the excess of the purchase price over the estimated fair value of the net assets acquired. The assignment of goodwill to our respective segments has not been completed at this time. The recorded goodwill related to the acquisition is deductible for tax purposes.

### Deferred taxes

The Meridian acquisition included taxable and nontaxable components resulting in differences in amounts recognized for GAAP and tax purposes. In both taxable and nontaxable business combinations, the amounts assigned to the individual assets acquired and liabilities assumed for financial statement purposes are often different from the amounts assigned or carried forward for tax purposes. We recorded a \$49.9 million deferred tax liability based on the estimated bases differences.

### Goodwill

A summary of changes in our goodwill by reportable segment is as follows for the three months ended March 31, 2019:

	Medicaid Health Plans	Medicare Health Plans	Not assigned <sup>(1)</sup>	Total
<b>Balance as of December 31, 2018</b>	\$ 274.7	\$ 392.3	\$ 1,560.7	\$ 2,227.7
Acquisition related adjustments	—	—	(21.3)	(21.3)
<b>Balance as of March 31, 2019</b>	<b>\$ 274.7</b>	<b>\$ 392.3</b>	<b>\$ 1,539.4</b>	<b>\$ 2,206.4</b>

(1) Goodwill related to our September 1, 2018 Meridian acquisition is considered preliminary, pending the final allocation of the applicable purchase price. The assignment of goodwill to our respective segments has not been completed at this time.

### Unaudited Pro Forma Financial Information

The results of operations and financial condition for the Meridian acquisition have been included in our condensed consolidated financial statements since the Effective Date. The unaudited pro forma financial information presented below reflects our 2018 acquisition of Meridian, assuming the acquisition occurred as of January 1, 2018. Pro forma results are not provided for the three months ended March 31, 2019, as Meridian's operations were included in our results of operations for this time period.

These pro forma results are based on estimates and assumptions and do not reflect any anticipated synergies, efficiencies or other cost savings that we expect to realize from the acquisition. The following unaudited pro forma results have been prepared for comparative purposes only and do not purport to be indicative of the results of operations that would have occurred had the acquisition actually consummated at January 1, 2018, or project the future results of the combined company.

(in millions, except per share data)	Pro Forma - Unaudited	
	Three Months ended March 31, 2018	
Total revenues	\$	5,673.6
Net income	\$	100.9
Earnings per common share:		
Basic	\$	2.02
Diluted	\$	2.00
Weighted average common shares outstanding:		
Basic		49,890,397
Diluted		50,446,757

The pro forma results presented in the schedule above include adjustments related to the following purchase accounting and other acquisition-related costs:

- Elimination of historical intangible asset amortization expense and addition of amortization expense based on the current preliminary values of identified intangible assets;
- Elimination of interest expense associated with retired obligations and addition of interest expense based on debt incurred to finance the Meridian transaction;
- Elimination of results for Meridian operations not acquired;
- Elimination of transaction and integration-related costs;
- Include 5,207,547 shares of our common stock issued to finance the Meridian transaction;
- Adjustments to align the acquisition to our accounting policies; and
- Tax effects of the adjustments noted above.

### 3. SEGMENT REPORTING

On a regular basis, we evaluate discrete financial information and assess the performance of our three reportable segments Medicaid Health Plans, Medicare Health Plans and Medicare PDPs, to determine the most appropriate use and allocation of Company resources.

We allocate premium revenue, medical benefits expense, Medicaid premium taxes, the 2018 ACA industry fee and goodwill to our reportable segments. We do not allocate to our reportable segments any other assets and liabilities, investment and other income, selling, general and administrative expenses ("SG&A"), depreciation and amortization, or interest expense. The Company's decision-makers primarily use premium revenue, medical benefits expense and gross margin to evaluate the performance of our reportable segments.

Our Corporate and Other category includes net investment and other income, SG&A expenses, depreciation, amortization and interest. Also included in this category are results for operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.

## Medicaid Health Plans

Our Medicaid Health Plans segment includes plans for beneficiaries of Temporary Assistance for Needy Families ("TANF"), Supplemental Security Income ("SSI"), Aged Blind and Disabled ("ABD"), Children's Health Insurance Program ("CHIP") and Long-Term Services and Supports ("LTSS") programs, among others. TANF generally provides assistance to low-income families with children. ABD and SSI generally provide assistance to low-income aged, blind or disabled individuals. CHIP provides assistance to qualifying families who are not eligible for Medicaid because their income exceeds the applicable income thresholds. The LTSS program is designed to help people with chronic illnesses or who have disabilities and need health and long-term care services, such as home care or adult day care, to enable them to stay in their homes and communities as long as possible.

Our Medicaid operations in Florida, Illinois and Kentucky individually account for 10% or more of our consolidated premium revenue for the three months ended March 31, 2019. These states and the respective Medicaid premium revenue as a percentage of total consolidated premium revenue are as follows:

	For the Three Months Ended March 31,	
	2019	2018
Florida	17%	13%
Illinois	13%	*
Kentucky	10%	15%

\*Our Illinois Medicaid health plan accounted for less than 10% of our consolidated premium revenue for the three months ended March 31, 2018.

In July 2018, we received a Notice of Intent to Award a five-year contract from the Florida Department of Health to provide statewide-managed care services to children with medically complex conditions through the Children's Medical Services Managed Care Plan ("CMS Plan"). The five-year contract award began on February 1, 2019; however, this contract is still subject to protest and appeal. Additionally, in April 2018, we received a Notice of Agency Decision from the Florida Agency for Health Care Administration ("AHCA") to award our subsidiary, Staywell, a new five-year contract to provide managed care services to Medicaid-eligible beneficiaries, including Managed Medical Assistance and Long-Term Care beneficiaries in 10 of 11 regions. As part of the Medicaid Managed Care program, we provide statewide-managed care services to beneficiaries in the Serious Mental Illness Specialty Plan; however, this contract is still subject to protest and appeal. We are one of two managed care plans providing services to the SMI beneficiaries. The new statewide Medicaid Managed Care program began on December 1, 2018.

## Medicare Health Plans

Medicare is a federal program that provides eligible persons age 65 and over and some disabled persons with a variety of hospital, medical and prescription drug benefits. MA is Medicare's managed care alternative to the original Medicare program, which provides individuals standard Medicare benefits directly through CMS. Our MA CCPs generally require members to seek health care services and select a primary care physician from a network of health care providers. In addition, we offer coverage of prescription drug benefits under the Medicare Part D program as a component of most of our MA plans.

## Medicare PDPs

We offer stand-alone Medicare Part D coverage to Medicare-eligible beneficiaries in our Medicare PDPs segment. The Medicare Part D prescription drug benefit is supported by risk sharing with the federal government through risk corridors designed to limit the losses and gains of the participating drug plans and by reinsurance for catastrophic drug costs. The government subsidy is based on the national weighted average monthly bid for this coverage, adjusted for risk factor payments. Additional subsidies are provided for dually-eligible beneficiaries and specified low-income beneficiaries. The Part D program offers national in-network prescription drug coverage that is subject to limitations in certain circumstances.

## Summary of Financial Information

Reportable operating segments are defined as components of an enterprise for which discrete financial information is available and evaluated on a regular basis by the enterprise's decision-makers to determine how resources should be allocated to an individual segment and to assess performance of those segments. Accordingly, we have three reportable segments: Medicaid Health Plans, Medicare Health Plans and Medicare PDPs.

A summary of financial information for our reportable segments through the gross margin level and reconciliation to income from operations is presented in the table below.

	Medicaid Health Plan	Medicare Health Plan	Medicare PDP	Corporate & Other	Consolidated
<b>For the Three Months Ended March 31, 2019</b>					
	(in millions)				
Premium	\$ 4,473.5	\$ 1,843.1	\$ 288.8	\$ 4.0	\$ 6,609.4
Products and services	—	—	—	115.8	115.8
Total premium and products and services revenues	4,473.5	1,843.1	288.8	119.8	6,725.2
Medical benefits	4,022.7	1,548.2	258.4	2.4	5,831.7
Costs of products and services	—	—	—	111.8	111.8
ACA industry fee	—	—	—	—	—
Medicaid premium taxes	31.7	—	—	—	31.7
Total gross margin expenses	4,054.4	1,548.2	258.4	114.2	5,975.2
Gross margin	419.1	294.9	30.4	5.6	750.0
Investment and other income	—	—	—	37.0	37.0
Other expenses	—	—	—	(602.9)	(602.9)
Income from operations	\$ 419.1	\$ 294.9	\$ 30.4	\$ (560.3)	\$ 184.1
<b>For the Three Months Ended March 31, 2018</b>					
Premium	\$ 2,809.9	\$ 1,556.5	\$ 259.9	\$ —	\$ 4,626.3
Products and services	—	—	—	—	—
Total premium and products and services revenues	2,809.9	1,556.5	259.9	—	4,626.3
Medical benefits	2,424.4	1,307.1	230.5	—	3,962.0
Costs of products and services	—	—	—	—	—
ACA industry fee	49.3	27.6	4.6	—	81.5
Medicaid premium taxes	32.1	—	—	—	32.1
Total gross margin expenses	2,505.8	1,334.7	235.1	—	4,075.6
Gross margin <sup>(1)</sup>	304.1	221.8	24.8	—	550.7
Investment and other income	—	—	—	19.9	19.9
Other expenses <sup>(2)</sup>	—	—	—	(409.4)	(409.4)
Income from operations	\$ 304.1	\$ 221.8	\$ 24.8	\$ (389.5)	\$ 161.2

(1) Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical expenses, cost of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the three months ended March 31, 2018 were adjusted to include Medicaid premium taxes, which decreased gross margin by \$32.1 million.



- (2) Effective July 1, 2018, other expenses include SG&A expenses, depreciation, amortization and interest. Accordingly, results for the three months ended March 31, 2018 were adjusted to exclude Medicaid premium taxes, which decreased other expenses by \$32.1 million.

#### 4. EQUITY AND EARNINGS PER SHARE

##### *Issuance of Common Stock*

In August 2018, we completed a public offering of our common stock and issued 5,207,547 shares of our common stock, at an offering price of \$265.00 per share. The net proceeds from the offering were approximately \$1.3 billion, after deducting underwriting discounts and offering costs of approximately \$37.7 million. We used the net proceeds to fund a portion of the acquisition of Meridian.

##### *Earnings per Common Share*

We compute basic earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding. We compute diluted earnings per common share on the basis of the weighted-average number of unrestricted common shares outstanding plus the dilutive effect of our stock-based compensation awards using the treasury stock method.

The calculation of the weighted-average common shares outstanding — diluted is as follows:

	For the Three Months Ended March 31,	
	2019	2018
Weighted-average common shares outstanding — basic	50,100,509	44,605,892
Dilutive effect of outstanding stock-based compensation awards	741,795	590,235
Weighted-average common shares outstanding — diluted	50,842,304	45,196,127
Anti-dilutive stock-based compensation awards excluded from computation	67,130	277,390

## 5. INVESTMENTS

The Company considers all of its investments as available-for-sale securities. Excluding restricted cash, cash equivalents and investments, the amortized cost, gross unrealized gains or losses and estimated fair value of short-term and long-term investments by security type are summarized in the following tables.

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Estimated Fair Value
<b>March 31, 2019</b>				
Debt securities:				
Asset-backed securities	\$ 154.2	\$ 0.2	\$ (0.3)	\$ 154.1
Corporate debt securities	1,127.9	3.5	(2.7)	1,128.7
Municipal securities	197.1	2.7	(0.1)	199.7
Residential mortgage-backed securities	10.1	—	(0.1)	10.0
Short-term time deposits	237.5	—	—	237.5
Government and agency obligations	9.2	—	(0.1)	9.1
Other securities	62.0	—	—	62.0
Total debt securities	1,798.0	6.4	(3.3)	1,801.1
Equity securities <sup>(1)</sup>	225.1	—	—	225.1
Total	\$ 2,023.1	\$ 6.4	\$ (3.3)	\$ 2,026.2
<b>December 31, 2018</b>				
Asset-backed securities	\$ 144.7	\$ —	\$ (0.5)	\$ 144.2
Corporate debt securities	943.0	0.5	(10.1)	933.4
Municipal securities	199.6	0.6	(0.9)	199.3
Residential mortgage-backed securities	7.2	—	(0.2)	7.0
Short-term time deposits	242.2	—	—	242.2
Government and agency obligations	44.9	—	(0.1)	44.8
Other securities	72.5	—	(0.1)	72.4
Total <sup>(1)</sup>	\$ 1,654.1	\$ 1.1	\$ (11.9)	\$ 1,643.3

(1) Investments in equity securities primarily consists of exchange traded funds in fixed income and preferred and hybrid securities. Equity securities were not material as of December 31, 2018.

Contractual maturities of debt securities at March 31, 2019 are as follows:

	Amortized Cost	Fair Value
Due in one year or less	\$ 889.6	\$ 889.7
Due after one year through five years	571.6	573.2
Due after five years through ten years	147.3	149.1
Due after ten years	13.1	12.9
Asset-backed and mortgage-backed securities	176.4	176.2
Total	\$ 1,798.0	\$ 1,801.1

Actual maturities may differ from contractual maturities due to the exercise of pre-payment options.

We sold available-for-sale investments totaling \$420.6 million and \$80.2 million during the three months ended March 31, 2019 and 2018, respectively. Realized gains and losses resulting from sales and redemptions of our available-for-sale investments were immaterial for all periods presented. Additionally, we did not realize any other-than-temporary impairment during any of these periods.

## 6. RESTRICTED CASH, CASH EQUIVALENTS AND INVESTMENTS

As a condition for licensure, we are required to maintain certain funds on deposit or pledged to various state agencies. Certain of our state contracts require the issuance of surety bonds. We classify restricted cash, cash equivalents and investments as long-term regardless of the contractual maturity date of the securities held, due to the nature of the states' requirements. The amortized cost, gross unrealized gains, gross unrealized losses and fair value of our restricted cash, cash equivalents and investment securities are as follows:

	<u>Amortized Cost</u>	<u>Gross Unrealized Gains</u>	<u>Gross Unrealized Losses</u>	<u>Estimated Fair Value</u>
<b>March 31, 2019</b>				
Cash	\$ 12.8	\$ —	\$ —	\$ 12.8
Money market funds	86.2	—	—	86.2
U.S. government securities and other	175.6	—	(0.3)	175.3
Total	<u>\$ 274.6</u>	<u>\$ —</u>	<u>\$ (0.3)</u>	<u>\$ 274.3</u>
<b>December 31, 2018</b>				
Cash	\$ 11.3	\$ —	\$ —	\$ 11.3
Money market funds	51.4	—	—	51.4
U.S. government securities and other	172.5	—	(0.5)	172.0
Total	<u>\$ 235.2</u>	<u>\$ —</u>	<u>\$ (0.5)</u>	<u>\$ 234.7</u>

Realized gains and losses on sales and redemptions of our restricted cash, cash equivalents and investments were not material for all periods presented.

## 7. STOCK-BASED COMPENSATION

Our Compensation Committee awards certain equity-based compensation under our stock plans, including restricted stock units ("RSUs") and performance stock units ("PSUs"). Compensation expense related to our stock-based compensation awards was \$22.8 million and \$12.1 million for the three months ended March 31, 2019 and 2018, respectively. As of March 31, 2019, there was \$121.0 million of unrecognized compensation cost related to unvested stock-based compensation arrangements that is expected to be recognized over a weighted-average period of 2 years. The unrecognized compensation cost for certain of our PSUs, which are subject to variable accounting, was determined based on our closing common stock price of \$269.75 as of March 29, 2019 and amounted to approximately \$33.9 million of the total unrecognized compensation cost. Due to the nature of the accounting for these awards, future compensation cost will fluctuate based on changes in our common stock price. We estimate stock-based compensation expense based on awards ultimately expected to vest over the related service period (generally the vesting period) of the award, or to an employee's eligible retirement date under the award agreement, if earlier. We make assumptions of forfeiture rates at the time of grant and continuously reassess our assumptions based on actual forfeiture experience.

A summary of RSU and PSU award activity, at target, for the three months ended March 31, 2019, is presented in the table below. For our PSUs, shares attained over target upon vesting are reflected as awards granted during the period, while shares canceled due to vesting below target are reflected as awards forfeited during the period.

	RSUs	PSUs	Total
Outstanding as of January 1, 2019	253,235	606,708	859,943
Granted	99,434	347,539	446,973
Vested	(99,668)	(351,648)	(451,316)
Forfeited	(2,372)	(8,276)	(10,648)
Outstanding as of March 31, 2019	250,629	594,323	844,952

The weighted-average grant-date fair value of all equity awards granted during the three months ended March 31, 2019 was \$205.27.

Refer to Note 2 - *Summary of Significant Accounting Policies* and Note 15 - *Stock-based Compensation* to the consolidated financial statements included in our 2018 Form 10-K for additional information regarding our equity-compensation awards and related compensation cost measurement.

## 8. DEBT

The following table summarizes our outstanding debt obligations and their classification in the accompanying condensed consolidated balance sheets (in millions):

	March 31, 2019	December 31, 2018
<i>Long-term debt, net:</i>		
5.25% Senior Notes, due April 1, 2025	\$ 1,200.0	\$ 1,200.0
5.375% Senior Notes, due August 15, 2026	750.0	750.0
Revolving Credit Facility	200.0	200.0
Debt issuance costs	(22.7)	(23.6)
Total long-term debt, net	\$ 2,127.3	\$ 2,126.4

### Senior Notes

In August 2018, we completed the offering and sale of 5.375% unsecured senior notes due 2026 in the aggregate principal amount of \$750.0 million (the "2026 Notes"). The aggregate net proceeds from the issuance of the 2026 Notes were used to fund a portion of the cash consideration for our acquisition of Meridian.

In March 2017, we completed the offering and sale of 5.25% unsecured senior notes due 2025 in the aggregate principal amount of \$1,200.0 million (the "2025 Notes"). The aggregate net proceeds from the issuance of the 2025 Notes were primarily used to redeem the full \$900.0 million aggregate principal amount of our 5.75% unsecured senior notes (the "2020 Notes") on April 7, 2017, and for general corporate purposes, including organic growth and working capital.

The 2026 Notes and 2025 Notes are classified as long-term debt in our condensed consolidated balance sheet at March 31, 2019, based on their maturity date. Refer to Note 10 - *Debt* to the consolidated financial statements included in our 2018 Form 10-K for additional information regarding these 2026 Notes and 2025 Notes, including applicable covenants.

### **Revolving Credit Facility**

In January 2016, we entered into a credit agreement, which provided for a senior unsecured revolving loan facility (the "Revolving Credit Facility"). In July 2018, this credit agreement was amended and restated ("Amended and Restated Credit Agreement") to increase the aggregate principle amount available under our Revolving Credit Facility from \$1.0 billion to \$1.3 billion, extend the maturity date for borrowings under the Revolving Credit Facility from January 2021 to July 2023 and decrease the applicable margins for borrowings under the Revolving Credit Facility, as calculated in accordance with the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement also includes an accordion feature which allows the Company to increase the total commitments under the Revolving Credit Facility by up to an additional \$500 million, subject to certain conditions.

Unutilized commitments under the Amended and Restated Credit Agreement are subject to a fee of 0.20% to 0.30% depending upon our ratio of total debt to consolidated EBITDA, as calculated in accordance with the Amended and Restated Credit Agreement.

As of March 31, 2019, \$200.0 million was outstanding under the Revolving Credit Facility, which was drawn during the third quarter of 2018 to fund a portion of the Meridian acquisition in September 2018. These borrowings are classified as long-term debt in accordance with the contractual terms of the Amended and Restated Credit Agreement.

Subsequent to the balance sheet date, in April 2019, an additional \$140.0 million was drawn on our Revolving Credit Facility for general corporate purposes, including organic growth and working capital.

As of March 31, 2019, and the date of this filing, we were in compliance with all covenants under the 2026 Notes, the 2025 Notes and the Amended and Restated Credit Agreement.

## **9. FAIR VALUE MEASUREMENTS**

Our condensed consolidated balance sheets include the following financial instruments: cash and cash equivalents, investments, receivables, accounts payable, medical benefits payable, long-term debt, including any current portion of long-term debt, and other liabilities. We consider the carrying amounts of cash and cash equivalents, receivables, other current assets and current liabilities to approximate their fair value due to the short period of time between the origination of these instruments and the expected realization or payment. Certain assets and liabilities are measured at fair value on a recurring basis and are disclosed below. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see the consolidated financial statements and notes thereto included in our 2018 Form 10-K.

## Recurring Fair Value Measurements

Assets and liabilities measured at fair value on a recurring basis at March 31, 2019 are as follows:

	Carrying Value	Fair Value Measurements Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Investments:				
Debt securities:				
Asset-backed securities	\$ 154.1	\$ —	\$ 154.1	\$ —
Corporate debt securities	1,128.7	—	1,128.7	—
Municipal securities	199.7	—	199.7	—
Residential mortgage-backed securities	10.0	—	10.0	—
Short-term time deposits	237.5	—	237.5	—
Government and agency obligations	9.1	9.1	—	—
Other securities	62.0	49.7	12.3	—
Total debt securities	1,801.1	58.8	1,742.3	—
Equity securities <sup>(1)</sup>	225.1	220.9	4.2	—
Total investments	\$ 2,026.2	\$ 279.7	\$ 1,746.5	\$ —
Restricted cash, cash equivalents and investments:				
Cash	\$ 12.8	\$ 12.8	\$ —	\$ —
Money market funds	86.2	86.2	—	—
U.S. government securities and other	175.3	175.1	0.2	—
Total restricted cash, cash equivalents and investments	\$ 274.3	\$ 274.1	\$ 0.2	\$ —

(1) Investments in equity securities primarily consists of exchange traded funds in fixed-income and preferred and hybrid securities.

Assets and liabilities measured at fair value on a recurring basis at December 31, 2018 are as follows:

	Carrying Value	Fair Value Measurements Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>Investments:</b>				
Asset-backed securities	\$ 144.2	\$ —	\$ 144.2	\$ —
Corporate debt securities	933.4	—	933.4	—
Municipal securities	199.3	—	199.3	—
Residential mortgage-backed securities	7.0	—	7.0	—
Short-term time deposits	242.2	—	242.2	—
Government and agency obligations	44.8	44.8	—	—
Other securities	72.4	49.8	22.6	—
<b>Total Investments<sup>(1)</sup></b>	<b>\$ 1,643.3</b>	<b>\$ 94.6</b>	<b>\$ 1,548.7</b>	<b>\$ —</b>
<b>Restricted cash, cash equivalents and investments:</b>				
Cash	\$ 11.3	\$ 11.3	\$ —	\$ —
Money market funds	51.4	51.4	—	—
U.S. government securities and other	172.0	171.8	0.2	—
<b>Total restricted cash, cash equivalents and investments</b>	<b>\$ 234.7</b>	<b>\$ 234.5</b>	<b>\$ 0.2</b>	<b>\$ —</b>

(1) Equity securities were not material as of December 31, 2018.

The following table presents the carrying value and fair value of our long-term debt outstanding as of March 31, 2019 and December 31, 2018:

	Carrying Value	Fair Value Measurements Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Long-term debt - March 31, 2019	2,127.3	2,034.7	200.0	—
Long-term debt - December 31, 2018	2,126.4	1,885.2	200.0	—

The fair value of our 2026 Notes and 2025 Notes were determined based on quoted market prices; therefore, would be classified within Level 1 of the fair value hierarchy. The fair value of obligations outstanding under our Revolving Credit Facility, as of March 31, 2019 and December 31, 2018, approximated the carrying value and would be classified within Level 2 of the fair value hierarchy.

## 10. MEDICAL BENEFITS PAYABLE

A reconciliation of the beginning and ending balances of medical benefits payable, by segment, is as follows:

	For the three months ended March 31, 2019				
	Medicaid Health Plans	Medicare Health Plans	Medicare PDPs	Corporate and other <sup>(2)</sup>	Consolidated
Beginning balance <sup>(1)</sup>	\$ 2,012.8	\$ 823.5	\$ 59.1	\$ 2.0	\$ 2,897.4
Acquisitions	—	—	—	—	—
Medical benefits incurred related to:					
Current year	4,182.7	1,612.7	284.7	3.2	6,083.3
Prior years	(160.0)	(64.5)	(26.3)	(0.8)	(251.6)
Total	4,022.7	1,548.2	258.4	2.4	5,831.7
Medical benefits paid related to:					
Current year	(2,769.2)	(936.4)	(187.7)	(1.4)	(3,894.7)
Prior years	(1,147.9)	(451.7)	(21.6)	(0.6)	(1,621.8)
Total	(3,917.1)	(1,388.1)	(209.3)	(2.0)	(5,516.5)
Ending balance <sup>(1)</sup>	\$ 2,118.4	\$ 983.6	\$ 108.2	\$ 2.4	\$ 3,212.6

(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2019 include a premium deficiency reserve for our Illinois Medicaid programs ("Illinois PDR"), which amounted to \$6.6 million and \$16.1 million at March 31, 2019 and December 31, 2018, respectively. See Note 2 - *Summary of Significant Accounting Policies* in our 2018 Form 10-K for further discussion.

(2) The Corporate and Other category includes operating segments that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.

	For the three months ended March 31, 2018				
	Medicaid Health Plans	Medicare Health Plans	Medicare PDPs	Corporate and other	Consolidated
Beginning balance <sup>(1)</sup>	\$ 1,373.2	\$ 722.5	\$ 50.6	\$ —	\$ 2,146.3
Acquisitions	—	—	—	—	—
Medical benefits incurred related to:					
Current year	2,523.8	1,383.1	256.9	—	4,163.8
Prior years	(99.4)	(76.0)	(26.4)	—	(201.8)
Total	2,424.4	1,307.1	230.5	—	3,962.0
Medical benefits paid related to:					
Current year	(1,659.4)	(859.9)	(218.0)	—	(2,737.3)
Prior years	(758.6)	(389.3)	(12.8)	—	(1,160.7)
Total	(2,418.0)	(1,249.2)	(230.8)	—	(3,898.0)
Ending balance <sup>(1)</sup>	\$ 1,379.6	\$ 780.4	\$ 50.3	\$ —	\$ 2,210.3

(1) The Medicaid Health Plans and Consolidated beginning and ending balances for 2018 include a premium deficiency reserve for our Illinois Medicaid program ("Illinois PDR"), which amounted to \$41.0 million and \$45.6 million at March 31, 2018 and December 31, 2017, respectively.

We recognize the cost of medical benefits in the period in which services are provided, including an estimate of the cost of medical benefits incurred but not reported ("IBNR"). Medical benefits expense includes direct medical expenses and certain medically-related administrative costs. We evaluate our estimates of medical benefits payable as we obtain more complete claims information and medical expense trend data over time. We record differences between actual experience and estimates used to establish the liability, which we refer to as favorable and unfavorable prior year reserve developments, as increases or decreases to medical benefits expense in the period we identify the differences.



Medical benefits payable developed favorably by approximately \$251.6 million and \$201.8 million for the three months ended March 31, 2019 and 2018, respectively. The release of the provision for moderately adverse conditions included in our prior year estimates was substantially offset by the provision for moderately adverse conditions established for claims incurred in the current year. Accordingly, the favorable development in our estimate of medical benefits payable related to claims incurred in prior years does not directly correspond to a decrease in medical benefits expense recognized during the period in which the favorable development is recognized.

Excluding the prior year development related to the release of the provision for moderately adverse conditions, our estimates of consolidated medical benefits payable developed favorably by approximately \$108.2 million and \$71.5 million for the three months ended March 31, 2019 and 2018, respectively. Such amounts are net of the development relating to refunds due to government customers with minimum loss ratio provisions. The net favorable development recognized in both 2019 and 2018 resulted primarily due to a number of operational and clinical initiatives planned and executed, that contributed to lower than expected pharmacy and medical trends, and actual claim submission time being faster than we originally assumed (i.e., our completion factors were higher than we originally assumed) in establishing our medical benefits payable in the prior years. This development does not directly correspond to an increase in our current year operating results as these reductions were offset by estimated current period medical benefits expense when we established our estimate of the current year medical benefits payable. Both completion factor and medical trend assumptions are influenced by utilization levels, unit costs, mix of business, provider reimbursement levels, processing system conversions and changes, claim inventory levels, claim processing patterns, our ability and practices to manage medical and pharmaceutical costs, claim submission patterns and operational changes resulting from business combinations, among others. Our actual costs were ultimately less than expected.

Our Meridian acquisition in September 2018 resulted in an increase to medical benefits payable as of the acquisition date. See Note 2 - *Centene Plan of Merger and Acquisitions*, for additional information on the Meridian acquisitions.

## 11. LEASES

In determining whether a contract contains a lease, we assess whether the arrangement meets all three of the following criteria: 1) there is an identified asset; 2) we have the right to obtain substantially all the economic benefits from use of the identified asset; and 3) we have the right to direct the use of the identified asset. This involves evaluating whether we have the right to operate the asset or to direct others to operate the asset in a manner that it determines without the supplier having the right to change those operating instructions, as well as evaluating our involvement in the design of the asset.

We have right-of-use assets and liabilities for non-cancelable operating leases primarily for office space, data centers and other equipment. Our leases have remaining lease terms up to approximately 14 years. The depreciable life of assets and leasehold improvements are limited by the expected lease term. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.

For the three months ended March 31, 2019 operating lease expense of \$17.4 million, was recorded as SG&A expense in our condensed consolidated statement of comprehensive income.

Balance sheet information related to our operating leases was as follows:

	Classification	March 31, 2019
<b>Assets:</b>		
Right of use assets	Other assets	\$ 249.9
<b>Liabilities:</b>		
Current	Accounts payable and accrued expenses	\$ 32.9
Noncurrent	Other liabilities	235.6
<b>Total liabilities</b>		<b>\$ 268.5</b>

Maturities of our operating lease liabilities are as follows:

<b>Maturity of Operating Lease Liabilities</b>	<b>March 31, 2019</b>	
2019 (remaining)	\$	33.5
2020		44.9
2021		44.4
2022		40.4
2023		37.2
2024		34.9
Thereafter		114.7
Total lease payments	\$	350.0
Less: imputed interest	\$	81.5
Present value of lease liabilities	\$	268.5

As of March 31, 2019 the weighted-average remaining lease term was 8.5 years. Our lease agreements do not provide a readily determinable implicit rate nor is it available to us from our lessors. Instead, we estimate our incremental borrowing rate based on information available at lease commencement in order to discount lease payments to present value. The weighted-average discount rate of our operating leases was 5.9%, as of March 31, 2019.

Supplemental cash flow information related to our operating leases is as follows:

	<b>Three Months Ended March 31, 2019</b>	
Cash paid for operating leases	\$	11.6
Leased assets obtained in exchange for new operating lease liabilities		10.4

## 12. INCOME TAXES

Our effective income tax rate on pre-tax income was 18.1% for the three months ended March 31, 2019 compared with 35.8% for the three months ended March 31, 2018. The year-over-year decrease was primarily driven by the one-year moratorium on the non-deductible ACA industry fee for 2019 and higher excess tax benefits resulting from the settlement of stock-compensation awards in 2019.

There were no significant changes to unrecognized tax benefits for the three months ended March 31, 2019. Our unrecognized tax benefits are not expected to change significantly during the next 12 months.

## 13. DISCONTINUED OPERATIONS

On August 3, 2016, our subsidiary, Universal American, completed the sale of its Traditional Insurance business prior to our acquisition of Universal American. This was accomplished by selling two life insurance subsidiaries, while retaining ownership of a third life insurance subsidiary, American Progressive Life & Health Insurance of New York ("Progressive"). The sale of the Traditional Insurance business underwritten by Progressive was accomplished through a 100% quota-share reinsurance treaty with a wholly-owned subsidiary of Nassau Re, that, when considered in combination with other reinsurance transactions previously entered into, resulted in the reinsurance of all of the Traditional Insurance policies that were underwritten by Progressive. Accordingly, the discontinued Traditional Insurance business did not materially affect our condensed consolidated statements of comprehensive income for any of the periods presented.

In accordance with ASC 360-10, *Property, Plant and Equipment* and ASC 205-20, *Presentation of Financial Statements—Discontinued Operations*, the Traditional Insurance business has been reported in discontinued operations in this 2019 Form 10-Q.

The following table summarizes the total assets and liabilities of our discontinued operations:

	<u>March 31, 2019</u>	<u>December 31, 2018</u>
	(in millions)	
<b>Assets</b>		
Cash and cash equivalents	\$ 0.5	\$ 0.1
Investments	40.6	42.8
Reinsurance recoverables	165.7	170.2
Other assets	0.4	0.5
<b>Total Assets</b>	<u>\$ 207.2</u>	<u>\$ 213.6</u>
<b>Liabilities</b>		
Reserves and other policy liabilities	\$ 166.1	\$ 166.9
Other liabilities	41.1	46.7
<b>Total liabilities</b>	<u>\$ 207.2</u>	<u>\$ 213.6</u>

Progressive's traditional insurance products are reinsured under quota share coinsurance treaties with unaffiliated insurers, while the life insurance risks are reinsured under either quota share coinsurance or yearly-renewable term treaties with unaffiliated insurers. Under quota share coinsurance treaties, we pay the reinsurer an agreed upon percentage of all premiums and the reinsurer reimburses us that same percentage of any losses. In addition, the reinsurer pays us certain allowances to cover commissions, the cost of administering the policies and premium taxes. Under yearly-renewable term treaties, the reinsurer receives premiums at an agreed upon rate for its share of the risk on a yearly-renewable term basis. We also use excess of loss reinsurance agreements for certain policies whereby we limit our loss in excess of specified thresholds.

We evaluate the financial condition of our Traditional Insurance reinsurers and monitor concentrations of credit risk to minimize our exposure to significant losses from reinsurer insolvencies. We are obligated to pay claims in the event that a reinsurer to whom we have ceded an insured claim fails to meet its obligations under the reinsurance agreement. We are not aware of any instances where any of our reinsurers have been unable to pay any policy claims on any reinsured business.

## 14. COMMITMENTS AND CONTINGENCIES

### Indemnification Obligations

Under Delaware law, our charter and bylaws and certain indemnification agreements to which we are a party, we are obligated to indemnify, or we have otherwise agreed to indemnify, certain of our current and former directors, officers and associates with respect to current and future investigations and litigation, including the matters discussed in this note. The indemnification agreements for our directors and executive officers with respect to events occurring prior to May 2009 require us to indemnify an indemnitee to the fullest extent permitted by law if the indemnitee was or is or becomes a party to or a witness or other participant in any proceeding by reason of any event or occurrence related to the indemnitee's status as a director, officer, associate, agent or fiduciary of the Company or any of our subsidiaries. The indemnification agreements require us to indemnify an indemnitee against all expenses, including attorney's fees, judgments, fines, settlement amounts and interest and other charges, and any taxes as a result of the receipt of payments under the indemnification agreement. We will not indemnify the indemnitee if not permitted under applicable law. We are required to advance all expenses incurred by the indemnitee. We are entitled to reimbursement by an indemnitee of expenses advanced if the indemnitee is not permitted to be reimbursed under applicable law after a final judicial determination is made and all rights of appeal have been exhausted or lapsed.

We amended and restated our indemnification agreements in May 2009. The revised agreements apply to our officers and directors with respect to events occurring after that time. Pursuant to the 2009 indemnification agreements, we will indemnify the indemnitee against all expenses, including attorney's fees, judgments, penalties, fines, settlement amounts and any taxes imposed as a result of payments made under the indemnification agreement incurred in connection with any proceedings that relate to the indemnitee's status as a director, officer or associate of the Company or any of our subsidiaries or any other enterprise that the indemnitee was serving at our request. We will also indemnify for expenses incurred by an indemnitee if the indemnitee, by reason of his or her corporate status, is a witness in any proceeding. Further, we are required to indemnify for expenses incurred by an indemnitee in defense of a proceeding to the extent the indemnitee has been successful on the merits or otherwise. Finally, if the indemnitee is involved in certain proceedings as a result of the indemnitee's corporate status, we are

required to advance the indemnitee's reasonable expenses incurred in connection with such proceeding, subject to the requirement that the indemnitee repay the expenses if it is ultimately determined that the indemnitee is not entitled to be indemnified. We are not obligated to indemnify an indemnitee for losses incurred in connection with any proceeding if a determination has not been made by the Board of Directors, a committee of disinterested directors or independent legal counsel in the specific case that the indemnitee has satisfied any standards of conduct required as a condition to indemnification under Section 145 of the Delaware General Corporation Law.

Pursuant to our obligations, we have advanced legal fees and related expenses to three former officers and two additional associates who were criminally indicted in connection with the government investigations of the Company that commenced in 2007 related to federal criminal health care fraud charges including conspiracy to defraud the United States, false statements relating to health care matters, and health care fraud in connection with their defense of criminal charges. In June 2013, the jury in the federal criminal trial reached guilty verdicts on multiple charges for the four individuals that were tried in 2013. In May 2014, the individuals were sentenced and our request for restitution was denied. All four individuals filed notices of appeal and the government filed notices of cross appeal on three of the four individuals, which the government has subsequently voluntarily dismissed. The appellate court affirmed the convictions in August 2016. Mr. Farha filed a petition for a writ of certiorari to the United States Supreme Court in January 2017. In April 2017, the United States Supreme Court declined to hear the appeal by Mr. Farha. The fifth individual, Mr. Bereday, entered a guilty plea in June 2017 in connection with the federal criminal charges, which was accepted by the court in July 2017. Mr. Bereday was sentenced in November 2017.

We have also previously advanced legal fees and related expenses to these five individuals regarding: a dispute in Delaware Chancery Court related to whether we were legally obligated to advance fees or indemnify certain of these individuals; the class actions titled *Eastwood Enterprises, L.L.C. v. Farha, et al.* and *Hutton v. WellCare Health Plans, Inc. et al.* filed in federal court; six stockholder derivative actions filed in federal and state courts between October 2007 and January 2008; an investigation by the United States Securities & Exchange Commission (the "Commission"); an action by the Commission filed in January 2012 against three of the five individuals, Messrs. Farha, Behrens and Bereday, and a *qui tam* action against Messrs. Farha, Behrens and Bereday in federal court. We settled the class actions in May 2011. In 2010, we settled the stockholder derivative actions and we were realigned as the plaintiff to pursue our claims against Messrs. Farha, Behrens and Bereday. Pursuant to the settlement agreements described below, Messrs. Farha, Behrens and Bereday were dismissed from the federal court and state derivative actions. Pursuant to the settlement agreement with Mr. Bereday described below, Mr. Bereday was dismissed from the fee advancement case in Delaware Chancery Court. The Commission action was closed in May 2018. The *qui tam* action is currently stayed and the stay is subject to being lifted at any time.

In April 2017, the Commission and Mr. Farha entered into a consent judgment to pay \$12.5 million to the Commission and \$7.5 million to us. In April 2017, the Commission and Mr. Behrens also entered into a consent judgment to pay \$4.5 million to the Commission and \$1.5 million to us. In May 2018, the Commission and Mr. Bereday entered into a consent judgment to pay \$4.5 million to the Commission and the case was closed.

In addition, we have advanced a portion of the legal fees and related expenses to Mr. Farha in connection with lawsuits he filed in Delaware and Florida state court to have certain restrictions lifted on WellCare stock purportedly awarded to him during his employment with us. The Delaware and Florida state court matters have been dismissed.

In September 2016, we entered into a settlement agreement with Mr. Farha pursuant to which he paid us \$7.5 million, as referenced in the April 2017 consent judgment with the Commission, and we agreed that we would not seek to recover additional legal fees previously advanced related to these matters, and that our obligation to continue advancing fees would be limited to no more than an additional \$7.5 million.

We also have advanced a portion of the legal fees and related expenses to Mr. Behrens in connection with his lawsuit in Delaware state court to have certain restrictions lifted on WellCare stock purportedly awarded to him during his employment with WellCare, which the court dismissed. In October 2016, we also entered into a settlement agreement with Mr. Behrens pursuant to which he paid us \$1.5 million, as referenced in the April 2017 consent judgment with the Commission, and we agreed that we would not seek to recover additional legal fees previously advanced in connection with these matters, and that our obligation to continue advancing fees would be limited to no more than an additional \$1.5 million.

In June 2017, we entered into a settlement agreement with Mr. Bereday that became effective in July 2017, pursuant to which we agreed that we would not seek to recover legal fees previously advanced in connection with these matters, and that our obligation to continue advancing fees would be limited to no more than an additional \$2.5 million.

In connection with these matters, we have advanced to the five individuals legal fees and related expenses from the inception of the investigations through March 31, 2019, the cumulative amounts of which has not changed materially from

December 31, 2018. We expense these costs as incurred and classify the costs as SG&A expense incurred in connection with the investigations and related matters.

We have exhausted our insurance policies related to reimbursement of our advancement of fees related to these matters. We are unable to estimate the total amount of these costs or a range of possible loss. Accordingly, we continue to expense these costs as incurred.

#### **Other Lawsuits and Claims**

Based on the nature of our business, we are subject to regulatory reviews or other investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities. These authorities regularly scrutinize the business practices of health insurance and benefits companies and their reviews focus on numerous facets of our business, including claims payment practices, provider contracting, competitive practices, commission payments, privacy issues and utilization management practices, among others. Some of these reviews have historically resulted in fines imposed on us and some have required changes to our business practices. We continue to be subject to such reviews, which may result in additional fines and/or sanctions being imposed, premium refunds or additional changes in our business practices.

Separate and apart from the legal matters described above, we are also involved in other legal actions in the normal course of our business, including, without limitation, protests and appeals related to Medicaid procurement awards, wage and hour claims and other employment claims, claims for indemnification under purchase agreements, vendor disputes and provider disputes regarding payment of claims. Some of these actions seek monetary damages including claims for liquidated or punitive damages, which are not covered by insurance. We review relevant information with respect to these litigation matters and we update our estimates of reasonably possible losses and related disclosures. We accrue an estimate for contingent liabilities, including attorney's fees related to these matters, if a loss is probable and estimable. Currently, we do not expect that the resolution of any of these currently pending actions, either individually or in the aggregate, will differ materially from our current estimates or have a material adverse effect on our results of operations, financial condition and cash flows. However, the outcome of any legal actions cannot be predicted, and therefore actual results may differ from those estimates.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

### Forward-Looking Statements

Statements contained in this Form 10-Q for the quarterly period ended March 31, 2019 ("2019 Form 10-Q"), which are not historical fact may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and we intend such statements to be covered by the safe harbor provisions for forward-looking statements contained therein. Such statements, which may address, among other things, our financial outlook, the timing of the launch of new programs, pending new Medicaid contracts, the appropriation and payment to us by state governments of Medicaid premiums receivable, approval, financial and other effects of the proposed acquisition of us (the "Centene Transaction") by Centene Corporation ("Centene"), rate changes, market acceptance of our products and services, our ability to finance growth opportunities, our ability to respond to changes in laws and government regulations, including any repeal, replacement or modification of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the "ACA"), implementation of our growth strategies, projected capital expenditures, liquidity and the availability of additional funding sources may be found in this Item of this 2019 Form 10-Q and elsewhere in this report generally. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "targets," "predicts," "potential," "continues" or the negative of such terms or other comparable terminology. Forward-looking statements involve risks and uncertainties, including economic, regulatory, competitive and other factors that may affect our business. Please refer to the Risk Factors in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 ("2018 Form 10-K") and in Part II, Item 1A of this 2019 Form 10-Q. These forward-looking statements are inherently susceptible to uncertainty and changes in circumstances, as they are based on management's expectations and beliefs about future events and circumstances. Given the risks and uncertainties inherent in forward-looking statements, any of our forward-looking statements could be incorrect and investors are cautioned not to place undue reliance on any of our forward-looking statements. Subsequent events and developments may cause actual results to differ, perhaps materially, from our forward-looking statements. We undertake no duty and expressly disclaim any obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

Our actual results may differ materially from those indicated by forward-looking statements as a result of various important factors, including the expiration, cancellation, delay, suspension or amendment of our state and federal contracts. In addition, our results of operations and estimates of future earnings depend, in large part, on accurately estimating and effectively managing health care benefits and other operating expenses. A variety of factors may affect our premium revenue, medical expenses, profitability, cash flows and liquidity, including the outcome of any protests and litigation related to Medicaid awards, our ability to meet the requirements of readiness reviews, competition, changes in health care practices, changes in the demographics of our members, changes in the eligibility for participation in government programs, and changes to eligibility certification requirements, higher than expected utilization of health care services by our members, changes in federal or state laws and regulations or their interpretations, inflation, provider contract changes, changes in or suspensions or terminations of our contracts with government agencies, new technologies, such as new, expensive medications, potential reductions in Medicaid and Medicare revenue, the appropriation and payment to us by state governments of Medicaid premiums receivable, our ability to negotiate actuarially sound rates, especially in new programs with limited experience, government-imposed surcharges, taxes or assessments, changes to how provider payments are made by governmental payors, the ability of state customers to launch new programs on their announced timelines, or at all, the timing of the approval by the Centers for Medicare & Medicaid Services ("CMS") of Medicaid contracts, or changes to the contracts or rates required to obtain CMS approval, major epidemics, disasters and numerous other factors affecting the delivery and cost of health care, such as major health care providers' inability to maintain their operations and our ability to implement health care value-added programs and our ability to control our medical costs and other operating expenses, including through our vendors. Governmental action or inaction could result in premium revenues not increasing to offset any increase in medical costs, the annual premium-based health insurance industry assessment (the "ACA industry fee") or other operating expenses. Once set, premiums are generally fixed for one-year periods and, accordingly, costs that exceed our estimates or our regulators' actuarial pricing assumptions during such periods generally may not be able to be recovered through higher premiums or rate adjustments. Furthermore, if we are unable to estimate accurately incurred but not reported medical costs in the current period, our future profitability may be adversely affected. Due to these factors and risks, we cannot provide any assurance regarding our future premium levels or our ability to control our future medical costs.

In addition, the risks and uncertainties include, but are not limited to

- failure to complete the Centene Transaction could have material adverse effects on our business, results of operations, financial condition and cash flows;

- our ability to pursue alternatives to the Centene Transaction is limited by provisions in the Merger Agreement (as defined herein), which could discourage a potential competing acquiror of us from making a favorable alternative transaction proposal and, in specified circumstances, could require us to pay substantial termination fees to Centene;
- the Centene Transaction is subject to the expiration or termination of applicable waiting periods and the receipt of approvals, consents or clearances from regulatory authorities that may impose conditions that could have an adverse effect on us or, if not obtained, could prevent completion of the Centene Transaction;
- we are subject to business uncertainties and contractual restrictions while the Centene Transaction is pending, which could materially adversely affect our business, results of operations, financial condition and cash flows;
- uncertainties associated with the Centene Transaction may cause a loss of management personnel and other key employees, and we may have difficulty attracting and motivating management personnel and other key employees which could materially adversely affect our business, results of operations, financial condition and cash flows;
- our progress on top priorities such as integrating care management, advocating for our members, building advanced relationships with providers and government partners;
- delivering prudent, profitable growth; and
- our ability to effectively identify, execute and integrate acquisitions and performance of our acquisitions once acquired, including the ability to achieve expected synergies of the Meridian acquisition within the expected time frames or at all, the ability to achieve accretion to WellCare's earnings, revenues or other benefits expected, disruption to business relationships, operating results, and business generally of WellCare and/or Meridian and the ability to retain Meridian employees, and our ability to address operational challenges relating to the integration of Meridian with our existing business.

Due to these factors and risks, we may be required to write down or take impairment charges of assets associated with acquisitions. Furthermore, at both the federal and state government levels, legislative and regulatory proposals have been made related to, or potentially affecting, the health care industry, including but not limited to, repeal, replacement or modification of the ACA, reform of the Medicaid and Medicare programs, limitations on managed care organizations, changes to membership eligibility, and benefit mandates. Any such legislative or regulatory action could have the effect of reducing the premiums paid to us by governmental programs, increasing our medical and administrative costs or requiring us to materially alter the manner in which we operate. We are unable to predict the specific content of any future legislation, action or regulation that may be enacted or when any such future legislation or regulation will be adopted. Therefore, we cannot predict accurately the effect or ramifications of such future legislation, action or regulation on our business, financial condition, results of operations, and/or cash flows.

## OVERVIEW

### Introduction

WellCare Health Plans, Inc. (the "Company," "we," "us," or "our") focuses primarily on providing government-sponsored managed care services to families, children, seniors and individuals with complex medical needs primarily through Medicaid, Medicare Advantage ("MA") and Medicare Prescription Drug Plans ("PDP"), as well as individuals in the Health Insurance Marketplace. As of March 31, 2019, we served approximately 6.3 million members nationwide. As of March 31, 2019, we operated Medicaid health plans, including states where we receive Medicaid premium revenues associated with dually eligible special needs plans, in Arizona, Florida, Georgia, Hawaii, Illinois, Kentucky, Michigan, Missouri, Nebraska, New Jersey, New York, South Carolina and Texas.

As of March 31, 2019, we also operated MA coordinated care plans ("CCPs") in Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana, Kentucky, Louisiana, Maine, Michigan, Mississippi, New Jersey, New York, North Carolina, Ohio, South Carolina, Tennessee and Texas, as well as stand-alone Medicare PDP nationwide.

### Summary of Consolidated Financial Results

Summarized below are the key highlights for the three months ended March 31, 2019. For additional information, refer to "Results of Operations" below, which discusses both consolidated and segment results.

- **Membership** at March 31, 2019 increased by 2.0 million, or 47.4%, compared with March 31, 2018. The increase was primarily driven by Meridian as well as organic growth in our Medicare PDP and Medicare Health Plans segments.

- **Premiums** increased 42.9% for the three months ended March 31, 2019, compared with the same period in 2018, reflecting our acquisition of Meridian in September 2018, additional members in our Florida and Arizona Medicaid health plans, and organic growth in our Medicare Health Plans and Medicare PDP segments. These increases were partially offset by the 2019 ACA Fee Moratorium (discussed in *Key Development and Accomplishments* below).
- **Net Income** increased \$49.7 million for the three months ended March 31, 2019, compared with the same period in 2018, primarily driven by organic growth, continued improvement in operation execution across all segments and the acquisition of Meridian in September 2018.

## Key Developments and Accomplishments

Presented below are key developments and accomplishments relating to progress on our business strategy that have affected, or are expected to affect, our results:

- On March 26, 2019, we entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Centene under which Centene will acquire us for a combination of cash and stock. Under the terms of the Merger Agreement, our shareholders will receive \$120.00 in cash and 3.38 shares of Centene common stock for each share of our common stock. The proposed transaction is subject to customary closing conditions, including, but not limited to, the approval of the Merger Agreement by our stockholders, the approval of the share issuance of Centene stock by Centene’s stockholders, and the receipt of U.S. federal antitrust clearance and certain other required regulatory approvals. The transaction is expected to close in the first half of 2020.
- In February 2019, we received notice from the North Carolina Department of Health and Human Services (“DHHS”) that we were awarded a contract to administer the state’s Medicaid Prepaid Health Plans, which is subject to a protest process. DHHS has selected four health plans, including us, to serve North Carolina’s Medicaid beneficiaries on a statewide basis. One additional health plan led by providers was selected to operate health plans in certain regions. The state is expected to implement the new managed care program, in two phases, for its 1.6 million Medicaid beneficiaries beginning November 1, 2019.
- Effective January 1, 2019, Congress approved a one-year moratorium of the ACA industry fee for 2019 (“2019 ACA Fee Moratorium”), which also eliminated the Medicaid ACA industry fee reimbursement from our state government partners for 2019.
- In November 2018, we completed the asset purchase of Aetna Inc.’s (“Aetna”) entire standalone Medicare Part D prescription drug plan membership (“Aetna Part D membership”) for total approximate consideration of \$107.2 million in cash, which is subject to certain true-up provisions. Per the terms of the agreements, Aetna will provide administrative services to, and retain financial risk of, the acquired Aetna Part D membership through 2019. Therefore, the Aetna Part D membership will be excluded from our membership and results of operations until January 1, 2020.
- In September 2018, we completed the acquisition of Meridian for approximately \$2.5 billion in cash. As a result of this transaction, we expanded our Medicaid portfolio through the addition of Michigan; expanded our Medicaid presence in Illinois; and acquired an integrated PBM platform. Meridian also serves MA members in Illinois, Indiana, Michigan and Ohio, as well as Health Insurance Marketplace members in Michigan.
- In July 2018, we received a Notice of Intent to Award a contract from the Florida Department of Health to provide statewide-managed care services to children with medically complex conditions through the Children’s Medical Services Managed Care Plan (“CMS Plan”). The five-year contract award began on February 1, 2019; however, this contract is still subject to protest and appeal. Additionally, in April 2018, we received a Notice of Agency Decision from the Florida Agency for Health Care Administration (“AHCA”) to award our subsidiary, Staywell, a new five-year contract to provide managed care services to Medicaid-eligible beneficiaries, including Managed Medical Assistance and Long-Term Care beneficiaries in 10 of 11 regions. As part of the Medicaid Managed Care program, we provide statewide-managed care services to beneficiaries in the Serious Mental Illness Specialty Plan; however, this contract is still subject to protest and appeal. We are one of two managed care plans providing services to the SMI beneficiaries. The new statewide Medicaid Managed Care program began on December 1, 2018.



## RESULTS OF OPERATIONS

### Condensed Consolidated Financial Results

The following tables set forth condensed consolidated statements of operations data, as well as other key data used in our results of operations discussion for the three months ended March 31, 2019, compared with the same period in 2018.

	For the Three Months Ended March 31,		Percentage Change
	2019	2018	
Revenues:	(Dollars in millions)		
Premium	\$ 6,609.4	\$ 4,626.3	42.9%
Products and services	115.8	—	100.0%
Investment and other income	37.0	19.9	85.9%
Total revenues	6,762.2	4,646.2	45.5%
Expenses:			
Medical benefits	5,831.7	3,962.0	47.2%
Costs of products and services	111.8	—	100.0%
Selling, general and administrative	503.8	355.9	41.6%
ACA industry fee	—	81.5	100.0%
Medicaid premium taxes	31.7	32.1	(1.2)%
Depreciation and amortization	69.6	36.4	91.2%
Interest	29.5	17.1	72.5%
Total expenses	6,578.1	4,485.0	46.7%
Income before income taxes and equity in losses of unconsolidated subsidiaries	184.1	161.2	14.2%
Equity in earnings (losses) of unconsolidated subsidiaries	0.8	(2.7)	129.6%
Income before income taxes	184.9	158.5	16.7%
Income tax expense	33.5	56.8	(41.0)%
Net income	\$ 151.4	\$ 101.7	48.9%
Effective tax rate	18.1%	35.8%	(17.7)%

## Membership

In the following tables, we have summarized membership for our business segments in each state that exceeded 5% of our total membership, as well as all other states in the aggregate, as of March 31, 2019 and 2018, respectively.

State	March 31, 2019				Percentage of Total
	Medicaid Health Plans <sup>(1)</sup>	Medicare Health Plans <sup>(1)</sup>	Medicare PDPs	Total Membership	
Florida	1,008,000	104,000	65,000	1,177,000	18.7%
Illinois	801,000	27,000	57,000	885,000	14.0%
Michigan	502,000	22,000	57,000	581,000	9.2%
Georgia	492,000	52,000	24,000	568,000	9.0%
Kentucky	445,000	14,000	33,000	492,000	7.8%
Other states	873,000	339,000	1,394,000	2,606,000	41.3%
Health Insurance Marketplace <sup>(2)</sup>	—	—	—	7,000	0.1%
Total	4,121,000	558,000	1,630,000	6,316,000	100.0%

State	March 31, 2018				Percentage of Total
	Medicaid Health Plans <sup>(1)</sup>	Medicare Health Plans <sup>(1)</sup>	Medicare PDPs	Total Membership	
Florida	744,000	97,000	30,000	871,000	20.3%
Georgia	515,000	49,000	16,000	580,000	13.5%
Kentucky	459,000	12,000	22,000	493,000	11.5%
Missouri	281,000	—	15,000	296,000	6.9%
New York	149,000	88,000	54,000	291,000	6.8%
Illinois	123,000	16,000	35,000	174,000	4.1%
Other states	434,000	244,000	901,000	1,579,000	36.9%
Total	2,705,000	506,000	1,073,000	4,284,000	100.0%

(1) Medicaid Health Plans and Medicare Health Plans membership includes members who are dually-eligible and participate in both our Medicaid and Medicare programs. The dually-eligible membership was 74,000 and 51,000 of our Medicaid and Medicare membership as of March 31, 2019 and 2018, respectively.

(2) Health Insurance Marketplace, included in our Corporate and Other category as it does not meet the quantification thresholds required by generally accepted accounting principles and therefore not individually reportable, includes members from Michigan. Total Michigan membership is 588,000 members.

As of March 31, 2019, membership increased approximately 2.0 million members, or 47.4%, compared with March 31, 2018. Membership discussion by segment follows:

- **Medicaid Health Plans.** Membership increased by 1.4 million year-over-year, or 52.3%, to 4.1 million members as of March 31, 2019. The increase was primarily driven by the acquisition of Meridian in September 2018, as well as organic membership growth primarily in our Florida and Arizona Medicaid health plans. These increases were partially offset by net eligibility decreases in certain of our Medicaid markets.
- **Medicare Health Plans.** Membership as of March 31, 2019 increased by 52,000 year-over-year, or 10.3%, to 558,000 members. The increase is a result of the acquisition of Meridian and organic growth.
- **Medicare PDPs.** Membership as of March 31, 2019 increased 557,000 year-over-year, or 51.9%, to 1.6 million members. The increase was primarily the result of organic growth through a new enhanced product offering in 2019.

## Premium Revenue

Premium revenue increased by approximately \$2.0 billion, or 42.9%, for the three months ended March 31, 2019, compared with the same period in 2018, reflecting our acquisition of Meridian in September 2018, additional members in our Florida and Arizona Medicaid health plans and organic growth in both our Medicare Health Plans and Medicare PDP segments. The increase was partially offset by the effect of the 2019 ACA Fee Moratorium.

## Medical Benefits Expense

Medical benefits expense increased by approximately \$1.9 billion, or 47.2%, for the three months ended March 31, 2019, compared with the same period in 2018, primarily driven by the acquisition of Meridian in September 2018, additional members in our Florida and Arizona Medicaid health plans and organic growth in our Medicare Health Plans segment.

## Selling, General and Administrative ("SG&A") Expense

For the three months ended March 31, 2019 and 2018, when applicable, SG&A expense included certain transaction and integrations-related costs associated with our proposed acquisition by Centene, our acquisition of Aetna membership in December 2018, our acquisition of Meridian in September 2018 and our acquisition of Universal American in April 2017 ("transaction and integration costs"). These costs include severance payments, technology integration costs, advisory, legal and other professional fees that are reflected in SG&A expense in our condensed consolidated statements of comprehensive income. Additionally, for the three months ended March 31, 2018, SG&A expense under GAAP includes aggregate costs related to previously disclosed government investigations and related litigation and resolution costs ("investigation costs"). Refer to Note 14 - *Commitments and Contingencies* within the condensed consolidated financial statements included in this 2019 Form 10-Q for additional discussion of these investigation costs. Although the above items may recur, we believe that by providing non-GAAP measurements exclusive of these items, we facilitate period-over-period comparisons and provide additional clarity about events and trends affecting our core operating performance, as well as providing comparability to competitor results. The investigation costs are related to a discrete incident, which we do not expect to reoccur. The transaction and integration costs are related to specific events, which do not reflect the underlying ongoing performance of our business. The non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. Below is a reconciliation of these non-GAAP measures with the most directly comparable financial measure calculated in accordance with GAAP.

The reconciliation of SG&A expense, including and excluding such costs, is as follows:

	For the Three Months Ended March 31,	
	2019	2018
	(Dollars in millions)	
SG&A expense (GAAP)	\$ 503.8	\$ 355.9
Adjustments:		
Investigation costs	—	(0.1)
Transaction and integration costs	(9.8)	(2.7)
Adjusted SG&A expense (non-GAAP)	\$ 494.0	\$ 353.1
SG&A ratio (GAAP) <sup>(1) (3)</sup>	7.5%	7.7%
Adjusted SG&A ratio (non-GAAP) <sup>(2) (3)</sup>	7.3%	7.8%

(1) SG&A expense, as a percentage of total revenues.

(2) Adjusted SG&A expense, as a percentage of total revenues, excluding Medicaid premium tax reimbursement and Medicaid ACA industry fee reimbursements. Because reimbursements for Medicaid premium tax and ACA industry fee are both included in the premium rates or reimbursement established in certain of our Medicaid contracts and recognized separately as a component of expense, we exclude these reimbursements from total revenue when calculating key ratios as we believe that these components are not indicative of operating performance.

(3) Effective July 1, 2018, the Company redefined our SG&A ratio (GAAP) to be a percentage of total revenues. Adjusted SG&A ratio was redefined to be a percentage of total revenues excluding Medicaid premium tax reimbursement and Medicaid ACA industry fee reimbursement. Accordingly, results for the three months ended March 31, 2018 were adjusted to conform to this presentation. Our SG&A ratio (GAAP) and our Adjusted SG&A ratio for the three months ended March 31, 2018 did not change from the results previously reported.

Our SG&A expense, for the three months ended March 31, 2019, increased approximately \$147.9 million, compared with the same period in 2018. The increase was primarily the result of our acquisition of Meridian in September 2018, staffing and infrastructure costs to support organic growth and variable long-term management incentive compensation. Our SG&A ratio decreased 20 basis points for the three months ended March 31, 2019, compared with the same period in 2018 reflecting leverage in our SG&A on a higher revenue base as a result of our acquisition of Meridian in September 2018 and continued organic growth.

Our Adjusted SG&A expense, for the three months ended March 31, 2019, increased approximately \$140.9 million, compared with the same period in 2018. This increase was primarily the result of our acquisition of Meridian in September 2018, staffing and infrastructure costs to support organic growth and variable long-term management incentive compensation. Our Adjusted SG&A ratio decreased 50 basis points for the three months ended March 31, 2019, compared with the same period in 2018 reflecting leverage in our SG&A on a higher revenue base as a result of our acquisition of Meridian in September 2018 and continued organic growth.

### **Income Tax Expense**

Income tax expense for the three months ended March 31, 2019, decreased \$23.3 million, or 41%, compared with the same period in 2018. The effective tax rate, for the three months ended March 31, 2019, decreased to 18.1%, compared with 35.8% for the same period in 2018. The decrease in income tax expense and the effective tax rate is primarily driven by the effect of the 2019 ACA Fee Moratorium, partially offset by higher earnings before tax. The ACA industry fee, which was nondeductible for tax purposes, had the effect of increasing our income tax rate in 2018.

### **Segment Reporting**

Reportable operating segments are defined as components of an enterprise for which discrete financial information is available and evaluated on a regular basis by the enterprise's decision-makers to determine how resources should be allocated to an individual segment and to assess performance of those segments. Accordingly, we have three reportable segments: Medicaid Health Plans, Medicare Health Plans and Medicare PDPs.

#### *Segment Financial Performance Measures*

Our primary measurements of profitability for our reportable operating segments are premium revenue, gross margin and medical benefits ratio ("MBR"). Gross margin is defined as total revenues less investment and other income, medical benefits expense, costs of products and services, ACA industry fee expense and Medicaid premium tax expense. MBR measures the ratio of medical benefits expense to premium revenue. Our Adjusted MBR (non-GAAP) measures the ratio of medical benefits expense to premium revenue, excluding Medicaid premium taxes reimbursement and Medicaid ACA industry fee reimbursement.

We use gross margin, MBR and, where applicable, Adjusted MBR to monitor our management of medical benefits and medical benefits expense. These metrics are utilized to make various business decisions, including which health care plans to offer, which geographic areas to enter or exit and which health care providers to include in our networks.

For further information regarding premium revenues and medical benefits expense, please refer to "*Premium Revenue Recognition and Premiums Receivable*," and "*Estimating Medical Benefits Expense and Medical Benefits Payable*" in Part II – Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations, under "*Critical Accounting Estimates*" in our 2018 Form 10-K.

## Reconciling Segment Results

The following table reconciles our reportable segment results to income from operations, as reported in accordance with GAAP.

	For the Three Months Ended March 31,		Percentage Change
	2019	2018	
	(Dollars in millions)		
Gross Margin <sup>(1)</sup>			
Medicaid Health Plans	\$ 419.1	\$ 304.1	37.8%
Medicare Health Plans	294.9	221.8	33.0%
Medicare PDPs	30.4	24.8	22.6%
Corporate and Other <sup>(2)</sup>	5.6	—	100.0%
Total gross margin	750.0	550.7	36.2%
Investment and other income	37.0	19.9	85.9%
Other expenses <sup>(3)</sup>	(602.9)	(409.4)	47.3%
Income from operations	\$ 184.1	\$ 161.2	14.2%

(1) Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical benefits expense, costs of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the three months ended March 31, 2018 were adjusted to include Medicaid premium taxes, which decreased gross margin by \$32.1 million.

(2) Corporate and other category includes businesses that are not individually reportable because they do not meet the quantitative thresholds required by generally accepted accounting principles.

(3) Effective July 1, 2018, other expenses include SG&A expenses, depreciation, amortization and interest. Accordingly, results for the three months ended March 31, 2018 were adjusted to exclude Medicaid premium taxes, which decreased other expenses by \$32.1 million.

## Medicaid Health Plans

Our Medicaid Health Plans segment includes plans for beneficiaries of Temporary Assistance for Needy Families ("TANF"), Supplemental Security Income ("SSI"), Aged Blind and Disabled ("ABD"), Children's Health Insurance Program ("CHIP") and the Long-Term Services and Supports ("LTSS") program.

### Medicaid Health Plans Results of Operations

The following table sets forth the summarized results of operations and other relevant performance measures for our Medicaid Health Plans segment for the three months ended March 31, 2019 and 2018:

	For the Three Months Ended March 31,		Percentage Change
	2019	2018	
	(Dollars in millions)		
Premium revenue <sup>(1)</sup>	\$ 4,441.8	\$ 2,713.1	63.7 %
Medicaid premium tax reimbursement <sup>(1)</sup>	31.7	32.1	(1.2)%
Medicaid ACA industry fee reimbursement <sup>(1)</sup>	—	64.7	100.0 %
Total premiums	4,473.5	2,809.9	59.2 %
Medical benefits expense	4,022.7	2,424.4	65.9 %
ACA industry fee	—	49.3	100.0 %
Medicaid premium tax	31.7	32.1	(1.2)%
Gross margin <sup>(2)</sup>	\$ 419.1	\$ 304.1	37.8 %
Medicaid Health Plans MBR <sup>(1)</sup>	89.9%	86.3%	3.6 %
Effect of:			
Medicaid premium taxes	0.7%	1.0%	
Medicaid ACA industry fee reimbursement	—%	2.1%	
Medicaid Health Plans Adjusted MBR <sup>(1)</sup>	90.6%	89.4%	1.2 %
Medicaid membership at end of period:	4,121,000	2,705,000	52.3 %

<sup>(1)</sup> For GAAP reporting purposes, Medicaid premium tax reimbursement and Medicaid ACA industry fee reimbursement are included in premium revenue to measure our MBR. Our Medicaid Health Plans Adjusted MBR measures the ratio of our medical benefits expense to premium revenue, excluding Medicaid premium tax reimbursement and Medicaid ACA industry fee reimbursement revenue. Because reimbursements for Medicaid premium tax and the ACA industry fee are both included in the premium rates or reimbursement established in certain of our Medicaid contracts and recognized separately as a component of expense, we exclude these reimbursements from premium revenue when calculating key ratios as we believe that these components are not indicative of operating performance.

<sup>(2)</sup> Effective July 1, 2018, the Company redefined gross margin as total revenues less investment and other income, medical benefit expense, costs of products and services, the ACA industry fee expense, and Medicaid premium tax expense. Accordingly, results for the three months ended March 31, 2018 were adjusted to include Medicaid premium taxes, which decreased gross margin by \$32.1 million.

Medicaid total premiums increased \$1.7 billion, or 59.2%, for the three months ended March 31, 2019, compared with the same period in 2018, primarily driven by our acquisition of Meridian in September 2018 and net organic growth, including additional members in our Florida and Arizona Medicaid health plans. The increases were partially offset by the effect of the 2019 ACA Fee Moratorium.

Excluding Medicaid premium taxes and the Medicaid ACA industry fee reimbursements, Medicaid premium revenue increased \$1.7 billion, or 63.7%, for the three months ended March 31, 2019 compared with the same period in 2018. The increase was primarily driven by our acquisition of Meridian in September 2018 and net organic growth, including additional members in our Florida and Arizona Medicaid health plans.

Medical benefits expense increased \$1.6 billion, or 65.9%, for the three months ended March 31, 2019 compared with the same period in 2018, primarily resulting from our acquisition of Meridian in September 2018 and net organic growth, including the additional members in our Florida and Arizona Medicaid health plans. These increases were partially offset by the favorable result of continued performance in clinical and pharmacy execution.

Our Medicaid Health Plans segment MBR increased 360 basis points, for the three months ended March 31, 2019, compared with the same period in 2018. The increase is primarily driven by our acquisition of Meridian in September 2018, net organic growth, and the effect of the 2019 ACA Fee Moratorium. These increases were partially offset by the favorable result of continued performance in clinical and pharmacy execution.

Excluding the effect of Medicaid premium taxes and Medicaid ACA industry fee reimbursements, our Medicaid Health Plans Adjusted MBR, for the three months ended March 31, 2019, increased by 120 basis points, compared with the same period in 2018. The increase is primarily driven by our acquisition of Meridian in September 2018 and net organic growth, partially offset by the favorable result of continued performance in clinical and pharmacy execution.

## Medicare Health Plans

We contract with CMS under the Medicare program to provide a comprehensive array of Part C and Part D benefits to Medicare eligible persons provided through our MA plans. Our MA plans are comprised of coordinated care plans ("CCPs"), which are primarily administered through HMOs and generally require members to seek health care services and select a primary care physician from a network of health care providers. Certain MA CCPs are administered through preferred provider organizations ("PPO") and private-fee-for-service ("PFFS"). In addition, we offer Medicare Part D coverage, which provides prescription drug benefits, as a component of most of our MA plans.

### Medicare Health Plans Results of Operations

The following table sets forth the summarized results of operations and other relevant performance measures for our Medicare Health Plans segment for the three months ended March 31, 2019 and 2018:

	For the Three Months Ended March 31,		Percentage Change
	2019	2018	
Medicare Health Plans:	(Dollars in millions)		
Premium revenue	\$ 1,843.1	\$ 1,556.5	18.4 %
Medical benefits expense	1,548.2	1,307.1	18.4 %
ACA industry fee	—	27.6	(100.0)%
Gross margin	\$ 294.9	\$ 221.8	33.0 %
MBR	84.0%	84.0%	— %
Membership	558,000	506,000	10.3 %

Medicare Health Plans premium revenue increased \$286.6 million, or 18.4%, for the three months ended March 31, 2019 compared with the same period in 2018, driven by organic growth and our acquisition of Meridian in September 2018.

Medical benefits expense increased \$241.1 million, or 18.4%, for the three months ended March 31, 2019 compared with the same period in 2018, driven by our acquisition of Meridian in September 2018 and organic growth. The Medicare Health Plans segment MBR is consistent with the same period in 2018.

## Medicare PDPs

We have contracted with CMS to serve as a plan sponsor offering stand-alone Medicare Part D PDPs to Medicare eligible beneficiaries through our Medicare PDPs segment. The PDP benefit design generally results in our incurring a greater portion of the responsibility for total prescription drug costs in the early stages of a plan year and less in the latter stages of a plan year due to the members' share of cumulative out-of-pocket costs increasing throughout the plan year. As a result, the Medicare PDPs' MBR is generally lower in the second half of the year as compared with the first half. In addition, the level and mix of members who are auto assigned to us and those who actively choose our PDPs will affect the segment MBR pattern across periods.

### Medicare PDPs Results of Operations

The following table sets forth the summarized results of operations and other relevant performance measures for our Medicare PDPs segment for the three months ended March 31, 2019 and 2018:

	For the Three Months Ended March 31,		Percentage Change
	2019	2018	
Medicare PDPs:	(Dollars in millions)		
Premium revenue	\$ 288.8	\$ 259.9	11.1 %
Medical benefits expense	258.4	230.5	12.1 %
ACA industry fee	—	4.6	(100.0)%
Gross margin	\$ 30.4	\$ 24.8	22.6 %
MBR	89.5%	88.7%	0.8 %
Membership	1,630,000	1,073,000	51.9 %

As noted in the table above, Medicare PDPs premium revenue, medical benefits expense and MBR increased for the three months ended March 31, 2019, compared with the same period in 2018. The increases in premium revenue and medical benefits expense were primarily a result of our new enhanced product offering in 2019. The increase in Medicare PDP MBR was primarily a result of our 2019 bid position, partially offset by the performance of the new enhanced product offering in 2019 and continued performance in pharmacy execution.

## BUSINESS TRENDS AND INFLATION

Health care expenditures have grown consistently for many years, and we expect overall health care costs to continue to grow in the future due to inflation, evolving medical technology, pharmaceutical advancement, regulatory requirements, demographic trends in the U.S. population, and national interest in health and wellbeing. We use various strategies to mitigate the negative effects of health care cost inflation. Specifically, our health plans try to control medical and hospital costs through our state savings initiatives and contracts with independent providers of health care services. Through these contracted care providers, our health plans emphasize preventive health care and appropriate use of specialty and hospital services. Additionally, our contracts with states require actuarially sound premiums that include health care cost trend. While we currently believe our strategies to mitigate health care cost inflation will continue to be successful, competitive pressures, new health care and pharmaceutical product introductions, demands from health care providers and customers, applicable health care reform regulations, an increase in the expected rate of inflation for health care costs, or other factors may adversely affect our ability to control health care costs.

## OUTLOOK

We expect our full year 2019 premium revenue and medical benefits expense to increase, across all segments, as compared with the full year 2018. The increases are expected to be a result of our acquisition of Meridian in September 2018 and net organic growth across all of our segments. These increases will be partially offset by the effect of the 2019 ACA Fee Moratorium. Additionally, while we anticipate improved SG&A operating leverage associated with premium revenue growth and continued synergies from our acquisitions, we expect the aggregate 2019 SG&A expense, as compared to 2018, to increase resulting from our acquisition of Meridian in September 2018 and net organic growth across all of our segments. Our effective income tax rate is expected to decrease in 2019, compared to 2018, due to the 2019 ACA Fee Moratorium.



## LIQUIDITY AND CAPITAL RESOURCES

Each of our existing and anticipated sources of cash is affected by operational and financial risks that influence the overall amount of cash generated and the capital available to us. Additionally, we operate as a holding company in a highly regulated industry. The parent and other non-regulated companies ("non-regulated subsidiaries") are dependent upon dividends and management fees from our regulated subsidiaries, most of which are subject to regulatory restrictions. For a further discussion of risks that can affect our liquidity, see Part I – Item 1A – "Risk Factors" included in our 2018 Form 10-K.

### *Centene Merger Agreement*

The Merger Agreement includes restrictions on the conduct of our business prior to completion of the Centene Transaction or termination of the Merger Agreement, generally requiring us to conduct our business in the ordinary course. However, we are subject to various specified restrictions unless we obtain Centene's prior written consent, which may not be unreasonably withheld, delayed or conditioned, or expressly contemplated or permitted by the Merger Agreement or as required by applicable law. Among other things and in each case subject to certain exceptions, we may not:

- incur additional indebtedness (excluding borrowings under our Revolving Credit Facility that are used to manage our ordinary course cash flow needs);
- issue additional shares of our common stock, repurchase our common stock, or pay dividends;
- acquire assets, securities or property, dispose of businesses or assets; or
- authorize any payment of, accrual or commitment for capital expenditures in any calendar year that would exceed by more than 110% the aggregate amount of capital expenditures budgeted for such year.

## Liquidity

The Company maintains liquidity at two levels: the regulated subsidiary level and the non-regulated subsidiary level.

### Regulated subsidiaries

Our regulated subsidiaries' primary liquidity requirements include:

- payment of medical claims and other health care services;
- payment of certain Part D benefits paid for members on behalf of CMS;
- SG&A costs directly incurred or paid through a management services agreement to one of our non-regulated administrative and management services subsidiaries; and
- federal tax payments to the parent company under an intercompany tax sharing agreement.

Our regulated subsidiaries meet their liquidity needs by:

- generating cash flows from operating activities, mainly from premium revenue;
- receipts of prospective subsidy payments and related final settlements from CMS to reimburse us for certain Part D benefits paid for members on behalf of CMS;
- cash flows from investing activities, including investment income and sales of investments; and
- capital contributions received from our non-regulated subsidiaries.

We refer collectively to the cash, cash equivalents and investment balances maintained by our regulated subsidiaries as "regulated cash and investments." Our regulated subsidiaries generally receive premiums in advance of payments of claims for medical and other health care services; however, regulated cash and investments can fluctuate significantly in a particular period depending on the timing of receipts for premiums from our government partners. Our unrestricted regulated cash and investments were \$5.0 billion as of March 31, 2019, an approximate \$0.2 billion increase from \$4.8 billion at December 31, 2018, due primarily to earnings from operations and contributions received from the parent and non-regulated subsidiaries, partially offset by dividends paid to the unregulated subsidiaries.

Our regulated subsidiaries are each subject to applicable state regulations that, among other things, require the maintenance of minimum levels of capital and surplus. We continue to maintain significant levels of aggregate excess statutory capital and surplus in our regulated subsidiaries. See further discussion under *Regulatory Capital and Dividend Restrictions* below.

## Parent and Non-Regulated Subsidiaries

Liquidity requirements at the non-regulated parent and subsidiary level generally consist of:

- payment of administrative costs not directly incurred by our regulated operations, including, but not limited to, staffing costs, business development, rent, branding and certain information technology services;
- capital contributions paid to our regulated subsidiaries;
- capital expenditures;
- debt service; and
- federal and state tax payments.

Our non-regulated parent and subsidiaries normally meet their liquidity requirements by:

- management fees earned by our non-regulated administrator subsidiary under management services agreements;
- dividends received from our regulated subsidiaries;
- collecting federal and state tax payments from the regulated subsidiaries;
- proceeds from issuance of debt and equity securities; and
- cash flows from investing activities, including investment income and sales of investments.

Unregulated cash, cash equivalents and investments totaled approximately \$296.4 million as of March 31, 2019, a decrease of approximately \$219.6 million from \$516.0 million as of December 31, 2018. The decrease is primarily due to capital contributions to our regulated subsidiaries, the semi-annual interest payment for our 2026 Notes, partially offset by dividends from certain of our regulated subsidiaries.

## Medicare Part D Funding and Settlements

Funding may be provided to certain regulated subsidiaries from our unregulated subsidiaries to cover any shortfall resulting from the amount of Part D benefits paid for members on behalf of CMS that exceeds the prospective subsidy payments that these regulated subsidiaries receive from CMS. We receive certain Part D prospective subsidy payments from CMS for our MA and PDP members as a fixed monthly per member amount, based on the estimated costs of providing prescription drug benefits over the plan year, as reflected in our bids. A discussion of the subsidy components under Part D is included in Note 2 - *Summary of Significant Accounting Policies* to the consolidated financial statements included in our 2018 Form 10-K. The benefits include the catastrophic reinsurance, premium and cost sharing for low-income Part D members, for which CMS will fully reimburse these subsidies, or recoup overpaid subsidies made during the plan year, as part of its annual settlement process that occurs in the fourth quarter of the subsequent year.

## Cash Flow Activities

Our cash flows are summarized as follows:

	For the Three Months Ended March 31,	
	2019	2018
	(In millions)	
Net cash (used in) provided by operating activities	\$ (30.0)	\$ 445.7
Net cash used in investing activities	(487.5)	(240.6)
Net cash provided by financing activities	135.2	417.4
(Decrease) increase in cash, cash equivalents and restricted cash and cash equivalents	\$ (382.3)	\$ 622.5

## Cash Flows from Operating Activities

We generally receive premiums in advance of payments of claims for health care services; however, cash flows related to our operations can fluctuate significantly in a particular period depending on the timing of premium receipts from our government partners.

Net cash used in operating activities for the three months ended March 31, 2019 was \$30.0 million, compared with \$445.7 million of net cash provided by operating activities for the same period in 2018. The decrease is primarily due to the advance receipt of April 2018 CMS Medicare premium payments in March 2018 and the timing of Medicaid premium receivable receipts, partially offset by the timing of medical claims payments.

## Cash Flows from Investing Activities

Net cash used in investing activities for the three months ended March 31, 2019 was \$487.5 million, compared with \$240.6 million for the same period in 2018. The increase was primarily due to higher purchases of investments during the three months ended March 31, 2019.

## Cash Flows from Financing Activities

Cash flows from financing activities are primarily affected by net funds received or paid for the benefit of members of our MA and PDP plans, as well as taxes withheld at the end of the vesting period for our equity-compensation awards. Cash provided by financing activities for the three months ended March 31, 2019 was \$135.2 million, compared with approximately \$417.4 million for the same period in 2018, primarily driven by the following:

- Net funds received for the benefit of members was approximately \$170.7 million for the three months ended March 31, 2019, compared with \$416.2 million during the same period in 2018. These funds represent the net amounts of subsidies we received from CMS in connection with the low-income cost sharing, catastrophic reinsurance and coverage gap discount components of the Medicare Part D program related to the government's portion of financial responsibility, net of the amounts we paid for related prescription drug benefits, described above in "Medicare Part D Funding and Settlements." The decrease was primarily the result of the advance receipt of April CMS subsidy payments in March 2018 and our 2019 bid positioning, which resulted in lower payments received for 2019 net subsidies, and
- Taxes withheld upon vesting of our equity-compensation awards of \$36.8 million for the three months ended March 31, 2019, compared with \$20.2 million for the same period in 2018.

## Capital Resources

### Debt

#### 5.375% Senior Notes due 2026

On August 13, 2018, we completed the offering and sale of 5.375% unsecured senior notes due 2026 in the aggregate principal amount of \$750.0 million (the "2026 Notes"). The aggregate net proceeds from the issuance of the 2026 Notes were \$739.0 million, with the net proceeds from the offering being used to fund a portion of the cash consideration for our acquisition of Meridian in September 2018.

The 2026 Notes will mature on August 15, 2026, and bear interest at a rate of 5.375% per annum, payable semi-annually on February 15 and August 15 of each year, commencing on February 15, 2019.

The 2026 Notes were issued under an indenture, dated as of August 13, 2018 (the "2026 Indenture"), between the Company and The Bank of New York Mellon Trust Company, N.A. ("*BNY Mellon*"), as trustee. The 2026 Indenture under which the notes were issued contains covenants that, among other things, limit our ability and the ability of our subsidiaries under certain circumstances to:

- incur additional indebtedness and issue preferred stock;
- pay dividends or make other distributions;
- make other restricted payments and investments;

- sell assets, including capital stock of restricted subsidiaries;
- create certain liens;
- incur restrictions on the ability of restricted subsidiaries to pay dividends or make other payments, and in the case of our subsidiaries, guarantee indebtedness;
- engage in transactions with affiliates; and
- create unrestricted subsidiaries.

In addition, the 2026 Indenture requires that for the Company to merge, consolidate or sell all or substantially all of its assets, (i) either the Company must be the surviving entity, or the surviving entity or purchaser must be a U.S. entity; (ii) the surviving entity or purchaser must assume all the obligations of the Company under the 2026 Notes and the 2026 Indenture; (iii) no default or event of default (as defined under the Indenture) exists and (iv) the surviving entity, after giving pro forma effect to the transaction, (x) may incur at least \$1.00 of additional indebtedness pursuant to the fixed charge coverage ratio or (y) have a fixed charge coverage ratio that is no worse than the fixed charge coverage ratio of the Company without giving pro forma effect to the transactions.

#### **5.25% Senior Notes due 2025**

On March 22, 2017, we completed the offering and sale of our 2025 Notes in the aggregate principal amount of \$1,200.0 million, resulting in aggregate net proceeds of \$1,182.2 million. A portion of the net proceeds from the offering was used to repay the \$100.0 million outstanding under our Credit Agreement, and to redeem the full \$900.0 million aggregate principal amount of our 2020 Notes. The remaining net proceeds from the offering of the 2025 Notes were used for general corporate purposes, including organic growth and working capital.

The 2025 Notes were issued under an indenture, dated as of March 22, 2017 (the "Base Indenture"), as supplemented by the First Supplemental Indenture, dated as of March 22, 2017 (the "First Supplemental Indenture" and, together with the Base Indenture, the "2025 Indenture"), each between the Company and BNY Mellon, as trustee. The 2025 Indenture under which the notes were issued contains covenants that, among other things, limit our ability and the ability of our subsidiaries under certain circumstances to:

- incur additional indebtedness and issue preferred stock;
- pay dividends or make other distributions;
- make other restricted payments and investments;
- sell assets, including capital stock of restricted subsidiaries;
- create certain liens;
- incur restrictions on the ability of restricted subsidiaries to pay dividends or make other payments, and in the case of our subsidiaries, guarantee indebtedness;
- engage in transactions with affiliates; and
- create unrestricted subsidiaries.

In addition, the 2025 Indenture requires that for the Company to merge, consolidate or sell all or substantially all of its assets: (i) either the Company must be the surviving entity, or the surviving entity or purchaser must be a U.S. entity; (ii) the surviving entity or purchaser must assume all the obligations of the Company under the 2025 Notes and the 2025 Indenture; (iii) no default or event of default (as defined under the indenture) exists; and (iv) the surviving entity, after giving pro forma effect to the transaction, (x) may incur at least \$1.00 of additional indebtedness pursuant to the fixed charge coverage ratio or (y) have a fixed charge coverage ratio that is no worse than the fixed charge coverage ratio of the Company without giving pro forma effect to the transactions.

#### **Credit Agreement**

On July 23, 2018, we entered into an amended and restated credit agreement (the "Amended and Restated Credit Agreement") with JPMorgan Chase Bank, N.A., as administrative agent, and the other lenders party thereto. The Amended and Restated Credit Agreement, among other things, modified the terms of our senior unsecured revolving loan facility (the "Revolving Credit Facility") to (i) increase the total commitments under the Revolving Credit Facility from \$1.0 billion to \$1.3 billion and (ii) extend the maturity date under the Revolving Credit Facility from January 2021 to July 2023.

Unutilized commitments under the Amended and Restated Credit Agreement are subject to a fee of 0.20% to 0.30% depending upon our ratio of total debt to consolidated EBITDA, as calculated in accordance with the Amended and Restated Credit Agreement.

Revolving Credit Loans designated by us at the time of borrowing as “ABR Loans” that are outstanding under the Credit Agreement bear interest at a rate per annum equal to (i) the greatest of (a) the Prime Rate (as defined in the Credit Agreement) in effect on such day; (b) the Federal Reserve Bank of New York Rate (as defined in the Credit Agreement) in effect on such day plus 1/2 of 1%; and (c) the Adjusted LIBO Rate (as defined in the Credit Agreement) for a one-month interest period on such day plus 1%; plus (ii) the Applicable Rate. Revolving Credit Loans designated by us at the time of borrowing as “Eurodollar Loans” that are outstanding under the Credit Agreement bear interest at a rate per annum equal to the Adjusted LIBO Rate (as defined in the Credit Agreement) for the interest period in effect for such borrowing plus the Applicable Rate. Pursuant to the Amended and Restated Credit Agreement, the “Applicable Rate” decreased to a range of (A) 0.375% to 1.00% per annum for ABR Loans and (B) 1.375% to 2.00% per annum for Eurodollar Loans, in each case depending on our ratio of total debt to consolidated earnings before interest, taxes, depreciation and amortization (“EBITDA”), as calculated in accordance with the Amended and Restated Credit Agreement. The Amended and Restated Credit Agreement includes negative and financial covenants that limit certain of our and our subsidiaries’ activities, including (i) restrictions on our and our subsidiaries’ ability to incur additional indebtedness; and (ii) financial covenants that require (a) the ratio of total debt to consolidated EBITDA not to exceed a maximum and (b) a minimum interest expense and principal payment coverage ratio.

The Amended and Restated Credit Agreement also contains customary representations and warranties that must be accurate in order for us to borrow under the revolving credit facility. In addition, the Amended and Restated Credit Agreement contains customary events of default. If an event of default occurs and is continuing, we may be required immediately to repay all amounts outstanding under the Amended and Restated Credit Agreement. Lenders holding greater than 50% of the loans and commitments under the Amended and Restated Credit Agreement may elect to accelerate the maturity of the loans.

As of March 31, 2019 \$200.0 million was outstanding under our Revolving Credit Facility. Additionally, we were in compliance with all covenants under the 2026 Notes, the 2025 Notes and the Amended and Restated Credit Agreement as of March 31, 2019. For additional information on our long-term debt, see Note 10 - *Debt* in the consolidated financial statements included in our 2018 Form 10-K.

In April 2019, we drew an additional \$140.0 million under our Revolving Credit Facility for general corporate purposes, including organic growth and working capital.

#### *Initiatives to Increase Our Unregulated Cash*

Subject to certain restrictions under the Centene Merger Agreement, as discussed above, we may pursue alternatives to raise additional unregulated cash. Some of these initiatives may include, but are not limited to, obtaining dividends from certain of our regulated subsidiaries, provided sufficient capital in excess of regulatory requirements exists in these subsidiaries, and/or accessing the debt and equity capital markets. However, we cannot provide any assurances that we will obtain applicable state regulatory approvals for additional dividends to our non-regulated subsidiaries by our regulated subsidiaries or be successful in accessing the capital markets if we determine to do so. We believe that we have sufficient capital, or sufficient access to capital, including through the Revolving Credit Facility, to meet our capital needs for at least the next twelve months.

#### *Regulatory Capital and Dividend Restrictions*

Each of our HMO and insurance subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulation. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our HMO and insurance subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus requirement, or net assets, for these subsidiaries was approximately \$1.7 billion and \$1.6 billion at March 31, 2019 and December 31, 2018, respectively. Our HMO and insurance subsidiaries were in compliance with these minimum capital requirements.

Under applicable regulatory requirements at March 31, 2019, the amount of dividends that may be paid through the remainder of 2019 by our HMO and insurance subsidiaries without prior approval by regulatory authorities is approximately \$0.5 billion in the aggregate. We received \$95.0 million in dividends from our regulated subsidiaries during the three-month period ended March 31, 2019, \$50.0 million of which required prior regulatory approval.

For additional information on regulatory requirements, see Note 16 – *Regulatory Capital and Dividend Restrictions* to the consolidated financial statements included in our 2018 Form 10-K.

## **CRITICAL ACCOUNTING ESTIMATES**

There have been no material changes in our critical accounting estimates during the three months ended March 31, 2019 from those previously disclosed in Part II – Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations, *Critical Accounting Estimates* in our 2018 Form 10-K.

### **Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

#### **Investment Return Market Risk**

As of March 31, 2019, we had cash and cash equivalents of \$3.2 billion, investments classified as current assets of \$1.0 billion, long-term investments of \$1.1 billion and restricted investments on deposit for licensure of \$274.3 million. The short-term investments classified as current assets consist of highly liquid securities with maturities between three and twelve months that are considered available for sale. Restricted assets consist of cash and cash equivalents and U.S. Treasury instruments deposited or pledged to state agencies in accordance with state rules and regulations. These restricted assets are classified as long term regardless of the contractual maturity date due to the nature of the states' requirements. The investments classified as long term are subject to interest rate risk and will decrease in value if market rates increase. Because of their contractual maturity dates, however, we would not expect the value of these investments to decline significantly as a result of a sudden change in market interest rates. Assuming a hypothetical and immediate 1% increase in market rates at March 31, 2019, the fair value of our fixed income investments would decrease by approximately \$26.7 million. Similarly, a 1% decrease in market interest rates at March 31, 2019 would increase the fair value of our investments by approximately \$26.7 million.

### **Item 4. Controls and Procedures.**

#### **Evaluation of Disclosure Controls and Procedures**

Our management carried out an evaluation required by Rule 13a-15 under the Exchange Act, under the leadership and with the participation of our Chief Executive Officer ("CEO") and Chief Financial Officer ("CFO"), of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15 under the Exchange Act ("Disclosure Controls"). Based on the evaluation, our CEO and CFO concluded that our Disclosure Controls were effective as of the end of the period covered by this 2019 Form 10-Q.

#### **Changes in Internal Control over Financial Reporting**

On September 1, 2018, we acquired Meridian Health Plan of Michigan, Inc., Meridian Health Plan of Illinois, Inc. and MeridianRx, LLC, a pharmacy benefit manager (collectively "Meridian"), which is included in the 2019 consolidated financial statements and constituted 11.0% of total consolidated assets as of March 31, 2019 and 21.6% of total consolidated revenues for the three months ended March 31, 2019. Refer to Note 2 - *Centene Plan of Merger and Acquisitions* of this 2019 Form 10-Q for further discussion of the Meridian acquisition.

We continue to integrate, implement, modify and evaluate processes, information technology systems and other components of internal control over financial reporting resulting from the acquisition of Meridian and such evaluation will be reported in management's annual assessment of internal control over financial reporting in our 2019 Annual Report on Form 10-K.

Excluding Meridian, there has not been any change in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) identified in connection with the evaluation required by Rule 13a-15(d) under the Exchange Act during the quarter ended March 31, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Part II – OTHER INFORMATION

### Item 1. Legal Proceedings.

For information regarding legal proceedings, see Note 14 – *Commitments and Contingencies* to the condensed consolidated financial statements of this Form 10-Q.

### Item 1A. Risk Factors.

In addition to the risk factors set forth in Part I - Item 1A - “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2018 (the “2018 Form 10-K”), investors should carefully consider the following risk factors, which relate to the proposed acquisition of us (the “Centene Transaction”) by Centene. These risks should be read in conjunction with the risk factors set forth in the 2018 Form 10-K and the other information contained in this report and our other filings with the Securities and Exchange Commission.

***The Centene Transaction is subject to conditions, some or all of which may not be satisfied, or completed on a timely basis, if at all. Failure to complete the Centene Transaction could have material adverse effects on our business, results of operations, financial condition and cash flows.***

The completion of the Centene Transaction is subject to a number of conditions, including, among others, (a) the adoption of the Merger Agreement by our stockholders, (b) the approval of the issuance of the shares of Centene common stock forming part of the merger consideration, as required by the listing standards of the New York Stock Exchange (the “Centene Stock Issuance”), by Centene’s stockholders, (c) the approval for listing on the New York Stock Exchange of the shares of Centene common stock to be issued in connection with the Centene Transaction, (d) the receipt of U.S. federal antitrust clearance and certain other required regulatory approvals, (e) the absence of any law or order prohibiting the consummation of the Centene Transaction or the Centene Stock Issuance, (f) the effectiveness of the registration statement on Form S-4 to be filed with the Securities and Exchange Commission by Centene for the registration of the Centene Stock Issuance under the Securities Act of 1933, (g) the absence of a material adverse effect on us or Centene, (h) no burdensome condition being a condition to the receipt of the U.S. federal antitrust clearance or the other required regulatory approvals and none of the U.S. federal antitrust clearance or the other required regulatory approvals containing, including or imposing any burdensome condition and (i) other conditions customary for a transaction of this type, which each and together make the timing and completion of the Centene Transaction uncertain.

Also, either we or Centene may terminate the Merger Agreement if the Centene Transaction has not been consummated by March 26, 2020 (subject to an automatic extension to August 26, 2020 in certain circumstances), except that this right to terminate the Merger Agreement will not be available to any party whose failure to perform any obligation under the Merger Agreement has been the cause of or the primary factor that resulted in the failure of the Centene Transaction to be consummated on or before that date.

If the Centene Transaction is not completed, our business, results of operations, financial condition and cash flows may be materially adversely affected and, without realizing any of the benefits of having completed the Centene Transaction, we will be subject to a number of risks, including the following:

- the market price of our common stock could decline;
- we could owe substantial termination fees to Centene under certain circumstances;
- if the Merger Agreement is terminated and our board of directors seeks another business combination, our stockholders cannot be certain that we will be able to find a party willing to enter into a transaction on terms equivalent to or more attractive than the terms that Centene has agreed to in the Merger Agreement;
- time and resources committed by our management to matters relating to the Centene Transaction could otherwise have been devoted to pursuing other beneficial opportunities for us;
- we may experience negative reactions from the financial markets or from our customers or employees; and
- we will be required to pay our costs relating to the Centene Transaction, such as legal, accounting, financial advisory and printing fees, whether or not the Centene Transaction is completed.

In addition, if the Centene Transaction is not completed, we could be subject to litigation related to any failure to complete the Centene Transaction or related to any enforcement proceeding commenced against us to perform our obligations under the Merger Agreement. The materialization of any of these risks could have material adverse effects on our business, results of operations, financial condition and cash flows.



Similarly, delays in the completion of the Centene Transaction could, among other things, result in additional transaction costs, loss of revenue or other negative effects associated with uncertainty about completion of the Centene Transaction.

***The Merger Agreement contains provisions that limit our ability to pursue alternatives to the Centene Transaction, which could discourage a potential competing acquiror of us from making a favorable alternative transaction proposal and, in specified circumstances, could require us to pay substantial termination fees to Centene.***

The Merger Agreement contains certain provisions that restrict our ability to solicit, initiate, knowingly facilitate or knowingly encourage or, subject to certain exceptions, engage in discussions or negotiations related to, or approve or recommend, any third-party proposal for an alternative acquisition transaction. Further, even if our board of directors withdraws or qualifies its recommendation with respect to the adoption of the Merger Agreement, unless the Merger Agreement has been terminated in accordance with its terms, we will still be required to submit the Centene Transaction-related proposals to a vote at the special meeting of our stockholders. In addition, Centene generally has an opportunity to offer to modify the terms of the transactions contemplated by the Merger Agreement in response to any third-party alternative acquisition proposal before our board of directors may withdraw or qualify its recommendation with respect to the Centene Transaction-related proposals.

Upon termination of the Merger Agreement, we will be required to pay to Centene (i) a termination fee of \$507,658,910, which increases to \$609,190,692 if such termination occurs after May 10, 2019, in connection with our acceptance of a superior proposal or a change of recommendation related thereto, (ii) a termination fee of \$640,431,240 if our Board changes its recommendation in connection with an intervening event, (iii) a termination fee of \$609,190,692 in the event we willfully breach our non-solicitation obligations in the Merger Agreement or (iv) a termination fee of \$171,823,016 if the required vote of our stockholders is not obtained. In addition, if we receive an acquisition proposal, the Merger Agreement is later terminated under certain circumstances and within 12 months after termination we enter into an agreement to sell more than 50% of our capital stock or assets, we will be required to pay Centene a termination fee of \$609,190,692, less any termination fee paid pursuant to clause (iv) above.

These provisions could discourage a potential third-party acquiror or merger partner that might have an interest in acquiring all or a significant portion of us or pursuing an alternative acquisition transaction from considering or proposing such a transaction, even if it were prepared to pay consideration with a higher per share cash or market value than the per share cash or market value proposed to be received or realized in the Centene Transaction. In particular, a termination fee, if applicable, may be substantial, and could result in a potential third-party acquiror or merger partner proposing to pay a lower price to our stockholders than it might otherwise have proposed to pay absent such a fee.

If the Merger Agreement is terminated and we determine to seek another business combination, we may not be able to negotiate a transaction with another party on terms comparable to, or better than, the terms of the Centene Transaction.

***The Centene Transaction is subject to the expiration or termination of applicable waiting periods and the receipt of approvals, consents or clearances from regulatory authorities that may impose conditions that could have an adverse effect on us or, if not obtained, could prevent completion of the Centene Transaction.***

Before the Centene Transaction may be completed, any waiting period (or extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 applicable to the Centene Transaction must have expired or been terminated and any approvals, consents or clearances required in connection with the Centene Transaction must have been obtained under applicable law. The terms and conditions of the approvals, consents and clearances that are granted may impose requirements, limitations or costs or place restrictions on the conduct of the combined company's business.

Under the Merger Agreement, we and Centene have agreed to use our respective reasonable best efforts to obtain such approvals, consents and clearances and therefore may be required to comply with conditions or limitations imposed by governmental authorities, except that Centene and its subsidiaries are not required to take actions that, individually or in the aggregate, would result in or would reasonably be expected to result in a burdensome condition.

In addition, regulators may impose conditions, terms, obligations or restrictions in connection with their approval of or consent to the Centene Transaction, including potential divestiture of assets, and such conditions, terms, obligations or restrictions may delay completion of the Centene Transaction or impose additional material costs on or materially limit the revenues of the combined company following the completion of the Centene Transaction. There can be no assurance that regulators will choose not to impose such conditions, terms, obligations or restrictions, and, if imposed, such conditions, terms, obligations or restrictions may delay or lead to the abandonment of the Centene Transaction.

***We are subject to business uncertainties and contractual restrictions while the Centene Transaction is pending, which could materially adversely affect our business, results of operations, financial condition and cash flows.***

In connection with the pendency of the Centene Transaction, it is possible that some customers, suppliers and other persons with whom we have a business relationship may delay or defer certain business decisions or might decide to seek to terminate, change or renegotiate their relationships with us as a result of the Centene Transaction, which could negatively affect our business, results of operations, financial condition and cash flows, as well as the market price of our common stock, regardless of whether the Centene Transaction is completed.

Under the terms of the Merger Agreement, we are subject to certain restrictions on the conduct of our business prior to completing the Centene Transaction, which may adversely affect our ability to execute certain of our business strategies, including the ability in certain cases to enter into or amend contracts, acquire or dispose of assets, incur indebtedness or incur capital expenditures. Such limitations could materially adversely affect our business, results of operations, financial condition and cash flows prior to the completion of the Centene Transaction.

Each of the risks described above may be exacerbated by delays or other adverse developments with respect to the completion of the Centene Transaction.

***Uncertainties associated with the Centene Transaction may cause a loss of management personnel and other key employees, and we may have difficulty attracting and motivating management personnel and other key employees, which could materially adversely affect our business, results of operations, financial condition and cash flows.***

We are dependent on the experience and industry knowledge of their management personnel and other key employees to execute our business plans. Our success depends in part upon our ability to attract, motivate and retain key management personnel and other key employees. Prior to completion of the Centene Transaction, current and prospective employees may experience uncertainty about their roles within the combined company following the completion of the Centene Transaction, which may have an adverse effect on our ability to attract, motivate or retain management personnel and other key employees.

***We and Centene may be targets of securities class action and derivative lawsuits that could result in substantial costs and may delay or prevent the Centene Transaction from being completed.***

Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. Even if the lawsuits are without merit, defending against these claims can result in substantial costs and divert management time and resources. An adverse judgment could result in monetary damages, which could have a negative impact on our and Centene's respective liquidity and financial condition. Additionally, if a plaintiff is successful in obtaining an injunction prohibiting completion of the Centene Transaction, then that injunction may delay or prevent the Centene Transaction from being completed, or from being completed within the expected timeframe, which may adversely affect our business, financial position and results of operation. Currently, we are not aware of any securities class action lawsuits or derivative lawsuits having been filed in connection with the Centene Transaction.

## **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

### **Recent Sales of Unregistered Securities**

None.

### **Issuer Purchases of Equity Securities**

None.

### **Dividends**

We have never paid cash dividends on our common stock. We currently intend to retain any future earnings to fund our business, and we do not anticipate paying cash dividends in the foreseeable future. In addition, our Amended and Restated Credit Agreement, the Indentures governing the 2026 Notes and the 2025 Notes and the Centene Merger Agreement include certain restrictions on our ability to pay cash dividends.

Our ability to pay dividends is partially dependent on, among other things, our receipt of cash dividends from our regulated subsidiaries. The ability of our regulated subsidiaries to pay dividends to us is limited by the state departments of insurance in

the states in which we operate or may operate, as well as requirements of the government-sponsored health programs in which we participate. Any future determination to pay dividends will be at the discretion of our board and will depend upon, among other factors, our results of operations, financial condition, capital requirements and contractual restrictions. For more information regarding restrictions on the ability of our regulated subsidiaries to pay dividends to us, please see Part I – Financial Information, Item 2 – *Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources*.

**Item 3. Defaults Upon Senior Securities.**

Not Applicable.

**Item 4. Mine Safety Disclosures.**

Not Applicable.

**Item 5. Other Information.**

Not Applicable.

**Item 6. Exhibits.**

Exhibits are incorporated herein by reference or are filed with this report as set forth in the Exhibit Index.

**EXHIBIT INDEX**

Exhibit Number	Description	INCORPORATED BY REFERENCE		
		Form	Filing Date with SEC	Exhibit Number
2.1	<a href="#">Agreement and Plan of Merger, dated as of March 26, 2019, by and among Centene Corporation, WellCare Health Plans, Inc., Wellington Merger Sub I, Inc. and Wellington Merger Sub II, Inc.</a>	8-K	March 27, 2019	2.1
10.1	<a href="#">Form of Stock Unit Award Agreement (effective January 1, 2019)*†</a>			
10.2	<a href="#">Form of Restricted Stock Unit Award Notice and Agreement (effective January 1, 2019)*†</a>			
10.3	<a href="#">Form of Performance Stock Unit Award Notice and Agreement (effective January 1, 2019)*†</a>			
31.1	<a href="#">Certification of Chief Executive Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 †</a>			
31.2	<a href="#">Certification of Chief Financial Officer pursuant to Section 302 of Sarbanes-Oxley Act of 2002 †</a>			
32.1	<a href="#">Certification of Chief Executive Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 †</a>			
32.2	<a href="#">Certification of Chief Financial Officer pursuant to Section 906 of Sarbanes-Oxley Act of 2002 †</a>			
101.INS	XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document ††			
101.SCH	XBRL Taxonomy Extension Schema Document ††			
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document ††			
101.LAB	XBRL Taxonomy Extension Label Linkbase Document ††			
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document ††			
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document ††			

\* Denotes a management contract or compensatory plan, contract or arrangement

† Filed herewith.

†† Furnished herewith and not filed for purposes of Section 11 and Section 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934.



5. Adjustments. If a Stock Unit is adjusted pursuant to Section 10(c) of the Plan, any such adjustment shall disregard any fractional Share and no Share will be delivered in connection with such fraction.

6. No Effect on Company Actions. Notwithstanding any term or provision of the Award Documentation to the contrary, the existence of the Award, or of any outstanding Stock Units awarded hereunder, shall not affect in any manner the right, power or authority of the Company to make, authorize or consummate: (a) any or all adjustments, recapitalizations, reorganizations, stock splits, stock dividends, combination of shares or other changes in the Company's capital structure or its business, (b) any merger, consolidation or similar transaction by or of the Company, (c) any offer, issue or sale by the Company of any

capital stock of the Company, including any equity or debt securities, or preferred or preference stock that would rank prior to or on parity with the Stock Units and/or that would include, have or possess other rights, benefits and/or preferences superior to those that the Stock Units include, has or possesses, or any warrants, options or rights with respect to any of the foregoing, (d) the dissolution or liquidation of the Company, (e) any sale, transfer or assignment of all or any part of the stock, assets or business of the Company or (f) any other corporate transaction, act or proceeding (whether of a similar character or otherwise).

7. Tax Withholding Obligations. As a condition of this Award, Participant will pay, or otherwise provide for, to the satisfaction of the Company, any applicable federal, state, local or foreign withholding taxes that may be due as a result of the vesting of Stock Units or the issuance of Shares under this Award. In the event that the Company determines that any payment of withholding or other taxes is required, the Company will have the right to: (a) require that Participant arrange such payments to the Company, or (b) cause an immediate forfeiture of Shares subject to the Stock Units granted pursuant to the Award Documentation with a Fair Market Value on the date of forfeiture equal to the withholding or other taxes due. In addition, in the Company's sole discretion and consistent with the Company's rules (including, but not limited to, compliance with the Company's Policy on Inside Information and Insider Trading) and regulations, the Company may permit Participant to pay the withholding or other taxes due as a result of the vesting of Participant's Stock Units by delivery (on a form acceptable to the Committee or Company) of an irrevocable direction to a licensed securities broker to sell Shares and to deliver all or part of the sales proceeds to the Company in payment of the withholding or other taxes. If Participant delivers to the Company Shares already owned by Participant as payment for any withholding or other tax obligations, (c) only a whole number of Shares (and not fractional Shares) may be delivered and (d) Shares must be delivered to the Company free and clear of any liens of any kind. Delivery for this purpose may, at the election of Participant, be made either by (e) physical delivery of the certificate(s) for all such Shares tendered in payment of the withholding or other tax obligations, accompanied by duly executed instruments of transfer in a form acceptable to the Company, or (f) direction to Participant's broker to transfer, by book entry, such Shares from a brokerage account of Participant to a brokerage account specified by the Company. If Shares are withheld from Participant to pay any withholding or other tax obligations, only a whole number of Shares (and not fractional shares) will be withheld in payment. The tax consequences to Participant (including without limitation federal, state, local and foreign income tax consequences) with respect to the Stock Units (including without limitation the grant, vesting and/or delivery thereof) are the sole responsibility of Participant. Participant shall consult with his or her own personal accountant(s) and/or tax advisor(s) regarding these matters and Participant's filing, withholding and payment (or tax liability) obligations.

8. Non-Transferability. Unless otherwise determined by the Committee, the Stock Units may not be transferred in any manner except by will or the laws of descent and distribution, and any attempt to transfer the Stock Units in violation of this Section 8 shall be void *ab initio*.

9. Amendment, Modification and Assignment. The Committee may amend or modify the Award Documentation at any time as provided by Sections 10(c) and Section 10(f) of the Plan and, if applicable, consistent with Appendix A of the Award Notice. This Award (and Participant's rights hereunder) may not be assigned, and the obligations of Participant hereunder may not be delegated, in whole or in part. The rights and obligations created hereunder shall be binding on Participant and his executors, administrators, and heirs, and on the successors and assigns of the Company.

10. Complete Agreement. The Award Documentation (together with the Plan and the Plan prospectus) constitute the entire agreement, and supersede all other prior agreements, understandings, representations and warranties, both written and oral, among the parties, with respect to the subject matter hereof.

11. No Right to Continued Employment or Service. The Award Documentation and the Award shall not confer, or be construed to confer, upon Participant any right to employment or service, or continued employment or service, with the Company or any of its Subsidiaries.

12. No Limit on Other Compensation Arrangements. Nothing contained in the Award Documentation shall preclude the Company or any of its Subsidiaries from adopting or continuing in effect any other or additional compensation plans, agreements or arrangements.

13. No Trust or Fund Created. Neither the Award Documentation nor the grant of Stock Units pursuant to the Award Documentation shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any of its Subsidiaries and Participant or any other person. To the extent that Participant or any other person acquires a right to receive payments from the Company or any of its Subsidiaries pursuant to the Award Documentation, such right shall be no greater than the right of any unsecured general creditor of the Company.

14. Section 409A. The Award Documentation shall be interpreted, administered and construed in a manner that is intended to avoid the imposition of interest, taxes and penalties on Participant pursuant to Section 409A of the Code. To the extent that any portion of the Stock Units constitutes "nonqualified deferred compensation" within the meaning of Section 409A of the Code, (a) to the extent required in order to avoid the imposition of any interest, penalties and additional tax under Section 409A of the Code, any Shares deliverable as a result of Participant's termination of Continuous Service will be delayed for six months and one day following such termination of Continuous Service, or if earlier, the date of Participant's death, if Participant is deemed to be a "specified employee" as defined in Section 409A of the Code and as determined by the Company, (b) any delivery of Shares provided for in the Award Documentation in connection with Participant's termination of Continuous Service shall be made to Participant only upon a "separation from service" (as such term is defined and used in Section 409A of the Code), and (c) each delivery of Shares made under the Award Documentation shall be treated as a separate payment for purposes of Section 409A of the Code. Notwithstanding the foregoing, the Company does not make any representation to Participant that the Stock Units awarded pursuant to this Award Documentation are exempt from, or satisfy, the requirements of Section 409A of the Code, and the Company shall have no liability or other obligation to indemnify or hold harmless Participant or any Beneficiary for any tax, additional tax, interest or penalties that Participant or any Beneficiary may incur in the event that any provision of this Award Documentation, or any amendment or modification thereof or any other action taken with respect thereto, is deemed to violate any of the requirements of Section 409A of the Code.

15. Interpretation; Construction. Participant accepts as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Award Documentation. Section, paragraph and other headings and captions are provided solely as a convenience to facilitate reference. Such headings and captions shall not be deemed in any way material or relevant to the construction, meaning or interpretation of the Award Documentation or any term or provision hereof.

16. Notices. Any notice under the Award Documentation shall be in writing addressed (a) if to the Company, to the attention of the Company's General Counsel at 8735 Henderson Road, Renaissance Two, Tampa, Florida 33634, or if the Company should move its principal office, to such principal office and (b) if to Participant, to Participant's last permanent address as shown on the Company's records, or to such other address as may be designated in a notice satisfying the requirements of this Section 16. Any notices shall be delivered personally or sent by registered or certified mail, postage prepaid, by facsimile (with proof of transmission), by courier (with proof of delivery) or by such other methods that are acceptable to the Company. Notice shall be deemed to have been duly given when delivered personally or when deposited in the United States mail or sent pursuant to such other method acceptable to the Company.

17. Non-Waiver of Breach. The waiver by any party hereto of the other party's prompt and complete performance, or breach or violation, of any term or provision of the Award Documentation shall be effected solely in a writing signed by such party, and shall not operate nor be construed as a waiver of any subsequent breach or violation, and the waiver by any party hereto to exercise any right or remedy which he or it may possess shall not operate nor be construed as the waiver of such right or remedy by such party, or as a bar to the exercise of such right or remedy by such party, upon the occurrence of any subsequent breach or violation.



18. Counterparts. The Award Documentation may be executed in two or more separate counterparts, each of which shall be an original, and all of which together shall constitute one and the same agreement.

19. Forfeiture and Company Right to Recover Fair Market Value of Shares Received Pursuant to Stock Units. This section sets forth circumstances under which Participant shall forfeit all or a portion of the Stock Units, or be required to repay the Company for the value realized in respect of all or a portion of the Stock Units.

(a) Fraud; Misconduct. In addition to the provisions set forth in Section 10(g) of the Plan, if, at any time, the Board or the Committee, as the case may be, in its sole discretion determines that any action or omission by Participant constituted (i) wrongdoing that contributed to (A) any material misstatement in or omission from any report or statement filed by the Company with the U.S. Securities and Exchange Commission or (B) a statement, certification, cost report, claim for payment, or other filing made under Medicare or Medicaid that was false, fraudulent, or for an item or service not provided as claimed, (ii) intentional or gross misconduct, (iii) a breach of a fiduciary duty to the Company or a Subsidiary, (iv) fraud or (v) non-compliance with the Company's Code of Conduct and Business Ethics, policies or procedures to the material detriment of the Company, then in each such case, commencing with the first fiscal year of the Company during which such action or omission occurred, Participant shall forfeit (without any payment therefore) up to 100% of any Stock Units that have not been vested or settled and shall repay to the Company, upon notice to Participant by the Company, up to 100% of the Fair Market Value of the Shares at the time such Shares were delivered to Participant pursuant to the Stock Units during and after such fiscal year. The Board or the Committee, as the case may be, shall determine in its sole discretion the date of occurrence of such action or omission, the percentage of the Stock Units that shall be forfeited and the percentage of the Fair Market Value of the Shares delivered pursuant to the Stock Units that must be repaid to the Company.

(b) Violation of Restrictive Covenants. In addition to the provisions set forth in Section 10(g) of the Plan, if Participant, during any period during which the applicable Stock Units are eligible to vest, without the consent of the Company, violates (i) a non-competition, non-solicitation, non-interference, non-disclosure, non-disparagement or other restrictive covenant obligation and/or confidentiality agreement or other agreement to which Participant is subject as of the date of Retirement or Disability (without regard to the post-employment duration of such covenant obligation, it being understood that, solely for purposes of this provision, the post-employment duration of such covenant obligation shall be deemed to extend through the end of the period during which the applicable Stock Units are eligible to vest) or (ii) any common law fiduciary duty or duty of loyalty to the Company or a Subsidiary, then any unvested Stock Units shall be immediately forfeited without any payment to Participant and shall become null and void.

20. Governing Law. The Award Documentation shall be governed by the corporate laws of the State of Delaware, without giving effect to any choice of law provisions.

21. Severability. If any term or provision of the Award Documentation is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or under any applicable law, rule or regulation, then such provision shall be construed or deemed amended to conform to applicable law (or if such provision cannot be so construed or deemed amended without materially altering the purpose or intent of the Award Documentation and the grant of Stock Units hereunder, such provision shall be stricken as to such jurisdiction and the remainder of the Award Documentation and the Award hereunder shall remain in full force and effect).

[\(Back To Top\)](#)

## **Section 3: EX-10.2 (FORM OF RESTRICTED STOCK AWARD NOTICE AND AGREEMENT)**

Exhibit 10.2

### **WELLCARE HEALTH PLANS, INC. 2013 INCENTIVE COMPENSATION PLAN RESTRICTED STOCK UNIT AWARD NOTICE AND AGREEMENT**

This award is made to the Participant named below by WellCare Health Plans, Inc., a Delaware corporation (the "**Company**"). Subject to the terms and conditions of this Restricted Stock Unit Award Notice and Agreement and the terms and conditions of the Stock Unit Award Agreement that is an integral part of this award (together, the "**Award Documentation**"), the Company hereby awards under the WellCare Health Plans, Inc. 2013 Incentive Compensation Plan (the "**Plan**") the Restricted Stock Units ("**RSUs**") described below to Participant effective as of the Grant Date set forth below. Capitalized terms used in the Award Documentation that are not defined herein have the meanings attributed to them in the Plan.

1. Participant: [●]
2. Grant Date: [●]
3. Number of RSUs Awarded: [●], subject to adjustment as provided in the Award Documentation and the Plan.
4. Description of RSUs: Each RSU constitutes an unfunded and unsecured promise of the Company to deliver one Share to Participant on the Delivery Date (defined below).
5. Normal Vesting Schedule: Except as set forth in Sections 7, 8 and 9 below, the following table sets forth each date upon which Participant shall become vested with respect to the number of RSUs set forth opposite such date (each such date, a "**Vesting Date**"), provided that the Continuous Service of Participant continues through and on the applicable Vesting Date. Except as otherwise provided in the Award Documentation, the RSUs shall vest only on the Vesting Dates specified in the table below and no partial vesting will occur prior to any Vesting Date.

Vest Date	Vest Quantity
-----------	---------------

6. Termination of Continuous Service: Except as set forth in Sections 7, 8 and 9 below, upon the termination of Participant's Continuous Service for any reason, any then-unvested RSUs shall be forfeited automatically without any payment to Participant and become null and void.

7. Change in Control: In the event of a Change in Control, any then-unvested RSUs shall become immediately vested on the effective date of the termination of Participant's Continuous Service if, within twenty-four (24) months following a Change in Control, Participant's Continuous Service is terminated (i) by the Company or a Subsidiary without Cause, (ii) by Participant for Good Reason, (iii) for Retirement or (iv) for Disability.

8. Retirement or Long-Term Disability: If Participant ceases to be an employee of the Company or a Subsidiary and either (i) Participant is eligible for Retirement at the time of such termination of employment and Participant's employment is terminated for Retirement or (ii) Participant's employment terminates due to Participant's Disability, then (x) if such termination occurs on or prior to the one-year anniversary of the Grant Date, (1) Participant shall retain a pro-rata portion of the RSUs (with such pro-rata portion determined by multiplying the total number of RSUs granted to Participant hereunder by a fraction, the numerator of which is the number of days from the Grant Date through the date of Participant's termination, and the denominator of which is 365), which retained RSUs shall continue to vest in equal installments on the applicable Vesting Dates as if such termination of employment had not occurred, and (2) any RSUs that are not retained by Participant

and otherwise eligible for continued vesting pursuant to the immediately preceding clause (x)(1) shall be forfeited automatically without any payment to Participant and become null and void, and (y) if such termination occurs following the one-year anniversary of the Grant Date, the RSUs shall continue to vest on the applicable Vesting Date as if such termination of employment had not occurred.

9. Death: If Participant dies while employed by the Company or a Subsidiary, any then-unvested RSUs shall become immediately vested.

10. Delivery Date: The Shares underlying the number of vested RSUs shall be delivered as soon as practicable and, in any case, within 30 days after the earlier of (i) the applicable Vesting Date on which such RSUs were originally scheduled to vest (not taking into account any acceleration of vesting pursuant to Section 7 or 8 of this Agreement) and (ii) the Participant's death.

Participant acknowledges and agrees that by accepting this Restricted Stock Unit Award Notice and Agreement electronically through the website of the agent appointed by the Company to administer the Plan, it will act as the Participant's electronic signature to this Restricted Stock Unit Award Notice and Agreement and Participant hereby consents and agrees to the electronic delivery of the Award Documentation. Participant acknowledges and agrees that (1) the Stock Unit Award Agreement, the Plan and the Plan prospectus are available for Participant's review through the website of the agent appointed by the Company to administer the Plan, and, upon request, a paper version of each document will be provided to Participant and (2) Participant has reviewed and fully understands the Award Documentation, the Plan and the Plan prospectus and agrees to be bound by the terms and conditions of the Plan and the Award Documentation.

2

[\(Back To Top\)](#)

## **Section 4: EX-10.3 (FORM OF PERFORMANCE STOCK UNIT AWARD NOTICE AND AGREEMENT)**

Exhibit 10.3

### **WELLCARE HEALTH PLANS, INC. 2013 INCENTIVE COMPENSATION PLAN PERFORMANCE STOCK UNIT AWARD NOTICE AND AGREEMENT**

This award is made to the Participant named below by WellCare Health Plans, Inc., a Delaware corporation (the "**Company**"). Subject to the terms and conditions of this Performance Stock Unit Award Notice and Agreement, including Appendix A attached hereto and incorporated herein, and the terms and conditions of the Stock Unit Award Agreement that is an integral part of this award (together, the "**Award Documentation**"), the Company hereby awards under the WellCare Health Plans, Inc. 2013 Incentive Compensation Plan (the "**Plan**") the Restricted Stock Units, the vesting of which is conditioned upon the achievement of one or more performance goals set forth on Appendix A attached hereto ("**PSUs**"), described below to Participant effective as of the Grant Date set forth below. Capitalized terms used in the Award Documentation that are not defined herein have the meanings attributed to them in the Plan.

1. Participant: [●]
2. Grant Date: [●]
3. Performance Period: [●]
4. Target Number of PSUs Awarded: [●], subject to adjustment as provided in the Award Documentation and the Plan. The actual number of PSUs that become eligible for vesting shall be determined by the Committee in accordance with Appendix A.
5. Vesting Date: Except as set forth in Sections 8, 9 and 10 below, [●] (the "**Vesting Date**").
6. Description of PSUs: Each PSU constitutes an unfunded and unsecured promise of the Company to deliver one Share to Participant on the Delivery Date (defined below).

7. Termination of Continuous Service: Except as set forth in Sections 8, 9 and 10 below, upon the termination of Participant's Continuous Service for any reason, any then-unvested PSUs shall be forfeited automatically without any payment to Participant and become null and void.

8. Change in Control: In the event of a Change in Control, the number of PSUs determined in accordance with Appendix A attached hereto shall become immediately vested on the earlier of (a) the Vesting Date set forth in Section 5 above or (b) the effective date of the termination of Participant's Continuous Service if, within twenty-four (24) months following a Change in Control, Participant's Continuous Service is terminated (i) by the Company or a Subsidiary without Cause, (ii) by Participant for Good Reason, (iii) for Retirement or (iv) for Disability.

9. Retirement or Long-Term Disability: If Participant ceases to be an employee of the Company or a Subsidiary and either (i) Participant is eligible for Retirement at the time of such termination of employment and Participant's employment is terminated for Retirement or (ii) Participant's employment terminates due to Participant's Disability, then following the end of the Performance Period, if and to the extent the Committee, in accordance with Section 4 above, determines that some number of PSUs will vest, Participant will, on the Vesting Date, vest in such number of PSUs determined as follows: (x) if such termination occurs on or prior to the one-year anniversary of the Grant Date, Participant shall vest in a pro-rata portion of the PSUs (with such pro-rata portion determined by multiplying the total number of PSUs that Participant would have otherwise earned as if such termination of employment had not occurred by a fraction, the numerator of which is the number of days from the Grant Date through the date of Participant's termination, and the denominator of which is 365), and (y) if such termination occurs following the one-year

anniversary of the Grant Date, Participant shall vest in the number of PSUs that would have been earned as if such termination of employment had not occurred.

10. Death: If Participant dies while employed by the Company or a Subsidiary, the Target Number of PSUs Awarded shall become immediately vested.

11. Cancellation: Any PSUs that do not vest pursuant to Sections 4, 8, 9 or 10 above on or before the Vesting Date shall be forfeited automatically on the Vesting Date without any payment to Participant and become null and void.

12. Delivery Date: The Shares underlying the number of vested PSUs shall be delivered as soon as practicable after the earlier of (i) the Vesting Date (not taking into account any acceleration of vesting pursuant to Sections 8 or 9 of this Agreement) and (ii) the Participant's death, but in no event later than March 15th of the year immediately following the year in which such PSUs vest.

Participant acknowledges and agrees that by accepting this Performance Stock Unit Award Notice and Agreement electronically through the website of the agent appointed by the Company to administer the Plan, it will act as the Participant's electronic signature to this Performance Stock Unit Award Notice and Agreement and Participant hereby consents and agrees to the electronic delivery of the Award Documentation. Participant acknowledges and agrees that (1) the Stock Unit Award Agreement, the Plan and the Plan prospectus are available for Participant's review through the website of the agent appointed by the Company to administer the Plan, and, upon request, a paper version of each document will be provided to Participant and (2) Participant has reviewed and fully understands the Award Documentation, the Plan and the Plan prospectus and agrees to be bound by the terms and conditions of the Plan and the Award Documentation.

[\(Back To Top\)](#)

## **Section 5: EX-31.1 (302 CERTIFICATION OF CEO)**

**EXHIBIT 31.1**

### CERTIFICATION

I, Kenneth A. Burdick, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of WellCare Health Plans, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

- d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
    - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
    - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 30, 2019

/s/ Kenneth A. Burdick

---

Kenneth A. Burdick

Chief Executive Officer

(Principal Executive Officer)

[\(Back To Top\)](#)

## Section 6: EX-31.2 (302 CERTIFICATION OF CFO)

**EXHIBIT 31.2**

### CERTIFICATION

I, Andrew L. Asher, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of WellCare Health Plans, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

- a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
- b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: April 30, 2019

/s/ Andrew L. Asher

\_\_\_\_\_  
Andrew L. Asher

Executive Vice President and Chief Financial Officer  
(Principal Financial Officer)

[\(Back To Top\)](#)

## Section 7: EX-32.1 (906 CERTIFICATION OF CEO)

EXHIBIT 32.1

CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO SECTION 906  
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of WellCare Health Plans, Inc. (the "Company") for the period ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Form 10-Q"), I, Kenneth A. Burdick, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 30, 2019

/s/ Kenneth A. Burdick

\_\_\_\_\_  
Kenneth A. Burdick

Chief Executive Officer  
(Principal Executive Officer)

[\(Back To Top\)](#)

## Section 8: EX-32.2 (906 CERTIFICATION OF CFO)

EXHIBIT 32.2

CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO SECTION 906  
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of WellCare Health Plans, Inc. (the "Company") for the period ended March 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the "Form 10-Q"), I, Andrew L. Asher, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Form 10-Q fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- (2) The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: April 30, 2019

/s/ Andrew L. Asher

---

Andrew L. Asher

Executive Vice President and Chief Financial Officer

(Principal Financial Officer)

[\(Back To Top\)](#)